Document:

Third Amendment to Lease dated October 18, 2011 between EOS Acquisition I LLC

 Exhibit 10.29.2 

THIRD AMENDMENT TO LEASE 
 THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is entered into as of the 18th day of October, 2011 by and between EOS ACQUISITION I LLC, a Delaware limited liability
company (“Landlord”), and SALIX PHARMACEUTICALS, INC., a California corporation (“Tenant”). Capitalized terms not otherwise defined herein shall have the meaning set forth in the Original Lease (hereinafter defined).

 W I T N E S S E T H: 
 WHEREAS, Colonnade Development, LLC, a Delaware limited liability company (“CD”) and Tenant entered into that certain Lease Agreement dated June 30, 2000, (the “Original
Lease”) as amended by a First Amendment to Lease dated September 9, 2004 (the “First Amendment”), and as amended by a Second Amendment to Lease dated February 11, 2011 (the “Second Amendment”) (collectively, the
“Lease”), whereby Landlord has leased to Tenant and Tenant has leased from Landlord approximately 26,363 rentable square feet as shown on Exhibit A-1 attached hereto and incorporated herein by reference (the “Existing
Premises”) located on the fifth (5th) floor of
the building commonly known as The Colonnade – Building One located in Raleigh, North Carolina (the “Building”); 

WHEREAS, CD transferred its interest in the Building and assigned all the leases in the Building to Landlord on October 3,
2006; 
 WHEREAS, Landlord and Tenant desire (i) to amend the terms of the Lease to expand the Premises and
(ii) modify other certain terms and conditions of the Lease as further described herein. 
 NOW, THEREFORE, for and
in consideration of the mutual covenants and promises herein contained, the receipt and adequacy of which are hereby acknowledged, the parties do hereby agree as follows: 
 1. Recitals. The recitals shall form a part of this Third Amendment. 
 2.
Expansion of the Premises. Effective as of November 1, 2011 (the “First Expansion Date”) the Existing Premises shall be expanded by adding 6,830 rentable square feet of space on the second floor (“Suite 210”) and
4,965 rentable square feet of space on the third floor (“Suite 312”) all as shown on Exhibit A-1 (Suite 210 and Suite 312 are collectively called the “First Expansion Space”), such that effective as of the First
Expansion Date and continuing throughout the balance of the Lease Term the Premises shall be redefined to be that area shown on Exhibit A-1 as the Existing Premises plus the First Expansion Space, totaling approximately 38,158 rentable
square feet of space. In the event the First Expansion Space has not been delivered to Tenant on the First Expansion Date then such date along with the dates noted below in Section 3 shall be adjusted on a day for day basis based on the date of
delivery of the First Expansion Space to Tenant. 
 3. Base Rent. Notwithstanding anything to the contrary in the Lease,
commencing on the First Expansion Date and continuing throughout the Term, Tenant shall begin paying Base Rent for the First Expansion Space as noted below and Base Rent for the Existing Premises, which remains unchanged, is provided below as well:

 Table of Base Rent for the Existing Premises 

 

													
	 Period
	  	Base Rental per
rentable 
square foot	 	  	Monthly
Base Rental	 	  	Annual
Base Rental	 
	 08/01/2011 – 03/31/2012
	  	$	21.00	  	  	$	0.00	  	  	 	N/A	  
	 04/01/2012 – 07/31/2012
	  	$	21.00	  	  	$	23,067.63	  	  	 	N/A	  
	 08/01/2012 – 07/31/2013
	  	$	21.58	  	  	$	23,704.73	  	  	$	284,456.76	  
	 08/01/2013 – 07/31/2014
	  	$	22.17	  	  	$	48,705.64	  	  	$	584,467.68	  
	 08/01/2014 – 07/31/2015
	  	$	22.78	  	  	$	50,045.76	  	  	$	600,549.12	  
	 08/01/2015 – 07/31/2016
	  	$	23.41	  	  	$	51,429.82	  	  	$	617,157.84	  
	 08/01/2016 – 07/31/2017
	  	$	24.05	  	  	$	52,835.85	  	  	$	634,030.20	  
	 08/01/2017 – 07/31/2018
	  	$	24.71	  	  	$	54,285.81	  	  	$	651,429.72	  

 Table of Base Rent for the First Expansion Space 

 

													
	 Period*
	  	Base Rental per
rentable 
square foot	 	  	Monthly
Base Rental	 	  	Annual
Base Rental	 
	 11/01/2011 – 05/31/2012**
	  	$	22.00	  	  	$	0.00	  	  	 	N/A	  
	 06/01/2012 – 10/31/2012***
	  	$	22.00	  	  	$	10,812.08	  	  	 	N/A	  
	 11/01/2012 – 10/31/2013***
	  	$	22.61	  	  	$	11,111.87	  	  	$	133,342.44	  
	 11/01/2013 – 10/31/2014
	  	$	23.23	  	  	$	22,833.15	  	  	$	273,997.80	  
	 11/01/2014 – 10/31/2015
	  	$	23.87	  	  	$	23,462.22	  	  	$	281,546.64	  
	 11/01/2015 – 10/31/2016
	  	$	24.52	  	  	$	24,101.12	  	  	$	289,213.44	  
	 11/01/2016 – 10/31/2017
	  	$	25.19	  	  	$	24,759.67	  	  	$	297,116.04	  
	 11/01/2017 – 07/31/2018
	  	$	25.89	  	  	$	25,447.71	  	  	 	N/A	  

  

	*	In the event the actual First Expansion Date is a date other than November 1, 2011, this rent schedule shall be adjusted based on the actual First Expansion Date
but in no event shall the Expiration Date change. 

	**	During this period Base Rent for the First Expansion Space shall completely abate as shown in the Base Rent table. 

	***	During this period Base Rent for the First Expansion Space shall abate by 50% as shown in the Base Rent table. 

4. Additional Rent. Tenant shall continue to pay the Operating Cost Escalation, as set forth in Section 4.2 of the Lease,
provided, however, the Operating Costs Expense Stop (as defined in Section 1.1 of the Lease) for the Existing Premises shall continue to be the actual Landlord’s Operating Costs incurred during calendar year 2011 on a per square foot basis
and for the First Expansion Space the Operating Costs Expense Stop shall be defined to be the actual Landlord’s Operating Costs incurred during calendar year 2012 on a per square foot basis. 

5. Delivery of the First Expansion Space. 
 a. Tenant acknowledges that it will accept and occupy the First Expansion Space in its “AS-IS, WHERE-IS” condition without any further improvements thereto by Landlord. Tenant shall be permitted
to perform renovations, alterations and improvements to the First Expansion Space at Tenant’s sole cost and expense, subject to subsection (b) below, in accordance with plans and specifications reasonably approved in advance by Landlord
(the “First Expansion Space Improvements”). The First Expansion Space Improvements shall be performed in accordance with the applicable terms of the Lease. 
 b. Provided that Tenant is not then in default under the Lease beyond the expiration of any applicable notice and grace periods, Landlord shall contribute up to $2.00 per rentable square foot of the First
Expansion Space, which equates to Twenty-Two Thousand Five Hundred Ninety and 00/100 

  
 2 

 
Dollars ($23,590.00) (the “First Expansion Space Allowance”) toward the cost of the First Expansion Space Improvements. Except as otherwise expressly provided herein, the First
Expansion Space Allowance shall be applicable only to the following costs: (i) any cost of installing improvements and alterations in the First Expansion Space as shown on plans approved by Landlord, (ii) design costs for architectural,
mechanical, plumbing and electrical design of the First Expansion Space Improvements, and (iii) construction documents and permits. Such items may include work Tenant is performing on behalf of a subtenant who will occupy the First Expansion
Space in accordance with the Lease. Prior to commencing any construction, Tenant shall provide Landlord with a copy of the contract between Tenant and its general contractor and copies of the applicable building permits, if any. Tenant shall also
provide Landlord with the dates such work is anticipated to commence and anticipated to be completed. Upon Tenant’s request, Landlord shall pay for those costs (to the extent covered by the First Expansion Space Allowance) directly to the
contractors and vendors, as requested by Tenant, based upon invoices submitted to Landlord. Landlord shall make such payments within thirty (30) days of Tenant’s request therefor which request must also contain the following: (a) the
contractor’s pay application (G702, G703) and (b) the general contractor’s conditional lien waivers. In the event that Tenant does not expend all of the First Expansion Space Allowance for costs within the First Expansion Space as
permitted hereunder on or before January 1, 2012, then Tenant may use any unused portion of the First Expansion Space Allowance for improvements within the Existing Premises based on invoices that are provided to Landlord which Landlord has not
already paid. Furthermore, in the event that Tenant does not expend all of the First Expansion Space Allowance for costs permitted hereunder on or before October 31, 2013, the unused portion of the First Expansion Space Allowance, if any, shall
be retained by Landlord and shall be deemed forfeited by Tenant. 
 c. Notwithstanding the foregoing, Landlord shall use
reasonable efforts to provide Tenant and Tenant’s licensed contractors with access to the First Expansion Space as soon as reasonably possible after the execution of this Third Amendment, provided (i) Tenant has obtained all insurance
required under the Lease to be maintained by Tenant, and (ii) Tenant’s access of the Premises prior to the First Expansion Date otherwise complies with all other applicable terms and conditions of the Lease. 

6. Sublease. Notwithstanding anything else to the contrary contained in the Lease, upon receipt of the subtenant information which
is required under Section 6.1.6 of the Lease, Landlord shall recognize WasteZero (“WasteZero”) as Tenant’s subtenant for Suite 312, so long as WasteZero does not pay more than 110% of the rent rate charged to Tenant for such
suite, for a period of three (3) years after the First Expansion Date and Landlord expressly waives any sublease fee due under the Lease for the WasteZero sublease. Additionally, during such period Tenant shall not be required to share any
overage amount paid by WasteZero above the Rent paid by Tenant with Landlord based on the WasteZero sublease and Tenant shall not lose any rights (renewal, expansion, or any other rights where subleasing space voids any rights) under the Lease for
subleasing part or all of the First Expansion Space to WasteZero as permitted herein. 
 7. Right of First Offer.

 Beginning on the first day after the First Expansion Date, the Right of First Offer contained in Section 12 of the
Second Amendment shall not apply to Suites 407 (the “Clinsys Space”) and 401 (the Hatteras Space”) of the Building as shown on Exhibit C attached hereto (collectively, the “Fourth Floor Offer Space”), but instead this
Section 7 shall apply to these spaces. 
 a. Provided (i) no Event of Default exists at the time or arises subsequent
thereto, which event by notice and/or the passage of time would constitute an Event of Default if not cured within the applicable cure period, and (ii) Tenant has not assigned this Lease nor sublet all or any portion of the Premises (other than
an assignment or sublease to a Related Assignee or a sublease of any portion of the First Expansion Space), beginning on the first day after the First Expansion Date and thereafter until the 

  
 3 

 
end of the First Extension, (x) Tenant shall have a right of first offer to lease the Clinsys Space beginning on December 1, 2014 in the event Clinsys does not exercise its right to
renew its lease of such space and (y) Tenant shall have a right of first offer to lease the Hatteras Space at the end of the current lease term for such space which shall occur on January 31, 2015. On or before December 5, 2013
Landlord shall notify Tenant in writing whether or not Clinsys exercised its renewal right and shall notify Tenant of the offer terms of the Clinsys Space, if available, and Hatteras Space including Landlord’s opinion of Fair Market Rental Rate
for both spaces as further defined below (the “Offer Terms”). Tenant shall then have five (5) business days to irrevocably notify Landlord that Tenant wishes to lease the Clinsys Space, if available, beginning on December 1, 2014
and to notify Landlord that Tenant wishes to lease the Hatteras Space beginning on February 1, 2015 in accordance with this Section 7. If Tenant elects only to lease the Clinsys Space (if available) or the Hatteras Space, but not both,
then the Offer Terms will include a term extension for the entire Premises until July 31, 2021 and if Tenant leases both the Clinsys Space and the Hatteras Space, then the Offer Terms will include a term extension for the entire Premises until
April 14, 2023. Once Tenant elects the applicable Fourth Floor Offer Space it will lease, then Landlord shall update the Offer Terms to include the rental rate for the applicable extension of the overall Premises which rental rate shall be
determined in accordance with the Fair Market Rental Rate determination as noted below. In the event Tenant leases the Clinsys Space or the Hatteras Space or both of these spaces in accordance with this Section 7, then the Extension Period as
defined in Section 11(a) of the Second Amendment shall change to a five (5) year renewal option. As noted above, the Offer Terms shall include a “Fair Market Rental Rate” for the applicable Fourth Floor Offer Space and for the
extension of the term of the remainder of the Premises in the method noted below. 
 b. As used above, the term “Fair
Market Rental Rate” shall mean the fair market rental rate that would be agreed upon between a landlord and a tenant entering into a new lease for comparable space as to location, configuration, size and use, in a comparable building as to
quality, reputation and age which is located in the Raleigh-Durham, North Carolina submarket, with a comparable build-out and a comparable term and comparable tenant credit, assuming the landlord and tenant are informed and well-advised and each is
acting in what it considers its own best interests when determining the Fair Market Rental Rate. Fair Market Rental Rate shall also address any construction allowances, concessions, free rent periods, annual escalations, operating expense structures
and all other financial components that are considered critical financial terms in a lease transaction. Landlord and Tenant shall negotiate in good faith to determine the Annual Base Rent for the applicable Fourth Floor Offer Space, for a period of
fifteen (15) days after the date on which Landlord receives Tenant’s written notice of Tenant’s irrevocable election to exercise the right of first offer. In the event Landlord and Tenant are unable to agree upon the Annual Base Rent
of the Extension Period within said fifteen (15) day period, the Fair Market Rental Rate for the applicable Fourth Floor Offer Space shall be determined by a board of three (3) licensed real estate brokers, one of whom shall be named by
the Landlord, one of whom shall be named by Tenant, and the two so appointed shall select a third. Each real estate broker so selected shall be licensed in the State of North Carolina as a real estate broker specializing in the field of office
leasing in Raleigh, North Carolina, having no fewer than ten (10) years experience in such field, and recognized as ethical and reputable within the field. Landlord and Tenant agree to make their appointments promptly within five (5) days
after the expiration of the fifteen (15) day period, or sooner if mutually agreed upon. The two (2) brokers selected by Landlord and Tenant shall promptly select a third broker within five (5) days after they both have been appointed,
and each broker, within five (5) days after the third broker is selected, shall submit his or her determination of the Fair Market Rental Rate. The Fair Market Rental Rate shall be the mean of the two closest rental rate determinations.
Landlord and Tenant shall each pay the fee of the broker selected by it, and they shall equally share the payment of the fee of the third broker. 
 c. Should Tenant elect to lease either of the Fourth Floor Offer Spaces hereunder, Tenant shall execute an amendment modifying the Lease within ten (10) days after Landlord presents same to Tenant,
which agreement shall set forth the new Lease Term, the Annual Base Rental and the 

  
 4 

 
other economic terms and provisions in effect for the Fourth Floor Offer Space. Should Tenant fail to execute the amendment (which amendment accurately sets forth the economic terms and
provisions as established) within ten (10) days after presentation of same by Landlord, time being of the essence, Tenant’s right to exercise the right of first offer on the applicable Fourth Floor Offer Space shall, at Landlord’s
sole option, terminate, and Landlord shall be permitted to lease such space to any other person or entity upon whatever terms and conditions are acceptable to Landlord in its sole discretion. 

d. Notwithstanding anything contained in this Section 7, in the event either the Clinsys Space or the Hatteras Space become
available earlier than as noted above due to a tenant default or other reason or in the event Tenant does not accept either space when offered to Tenant, then on any other occasion either space is available, other than as noted above, the provisions
of Section 12 of the Second Amendment shall apply to such space instead of this Section 7. 
 8. Broker.
Landlord and Tenant represent and warrant each to the other that they have not dealt with any broker(s) or any other person claiming any entitlement to any commission in connection with this transaction except CB Richard Ellis and Jones Lang LaSalle
(collectively, the “Broker(s)”). Tenant agrees to indemnify and save Landlord harmless from and against any and all claims, suits, liabilities, costs, judgments and expenses, including reasonable attorneys’ fees, for any leasing
commissions or other commissions, fees, charges or payments due, owing, or made to a broker (except as provided immediately below) in connection with this Third Amendment. Landlord agrees to indemnify and save Tenant harmless from and against any
and all claims, suits, liabilities, costs, judgments and expenses, including reasonable attorneys’ fees, for any leasing commissions or other commissions, fees, charges or payments due, owing, or made to a broker in connection with this Third
Amendment. Landlord expressly agrees and acknowledges that Landlord is responsible for the full payment of any leasing commissions due Broker(s) pursuant to a separate written agreement with such Broker(s). 

9. Ratification. Except as expressly or by necessary implication amended or modified hereby, the terms of the Lease are hereby
ratified, confirmed and continued in full force and effect, and Landlord and Tenant represent that neither has any knowledge of a default by the other under the Lease. 
 10. Commencement Agreement. Reference is made to the form of Declaration of Dates (the “Declaration”) attached hereto as Exhibit B. After the determination of the First Expansion Date
Landlord shall complete the Declaration and deliver the completed Declaration to Tenant. Within five (5) days after Tenant receives the completed Declaration from Landlord, Tenant shall execute and return the Declaration to Landlord to confirm
the First Expansion Date. Failure to execute the Declaration shall not affect the actual First Expansion Date. 
 11. Third
Floor Lobby Renovation. Landlord agrees to consult with Tenant regarding the third floor lobby renovation including without limitation, the reasonable selection of materials and finishes. 

12. Counterparts. This Third Amendment may be executed in any number of counterparts, each of which shall be an original, but all
of which taken together shall constitute one and the same instrument. A facsimile or PDF copy of a signature shall be as binding as an original copy and the parties expect to initially exchange PDF copies of their signatures in order to create a
binding agreement. 
 [SIGNATURE PAGE FOLLOWS] 

  
 5 

 IN WITNESS WHEREOF, the parties hereto have caused this Third Amendment to be
executed as of the day and year first above written. 
  

			
	LANDLORD:
	
	EOS Acquisition I LLC,
	a Delaware limited liability company
	
	By: KBS Realty Advisors, LLC,
	a Delaware limited liability company,
		
	By:	 	 /s/ Robin A.
Burke

			
	Name: Robin A. Burke
	Title: Senior Vice President
	
	TENANT:
	
	 SALIX PHARMACEUTICALS, INC.,
 a California corporation

		
	By:	 	 /s/ Adam C. Derbyshire

	Name:	 	 Adam C. Derbyshire

	Title:	 	 CFO

  
 6 

 EXHIBIT A-1 

DEPICTIONS OF THE EXISTING PREMISES 
 

 

  
 7 

 EXHIBIT A-1 

DEPICTION OF THE FIRST EXPANSION SPACE 
 SUITE 210 
 

 

  
 8 

 SUITE 312 
 

 

  
 9 

 EXHIBIT B 
 DECLARATION OF DATES 
 This Declaration Dates is made as of
                    , 20    , by EOS ACQUISITION I LLC (“Landlord”), and SALIX PHARMACEUTICALS, INC.
(“Tenant”), who agree as follows: 
 1. Landlord and Tenant entered into a Third Amendment dated
                    , 2011, in which Landlord leased to Tenant, and Tenant leased from Landlord, certain Premises described therein in the office
building located at 8540 Colonnade Center Drive, Raleigh, North Carolina 27615 (the “Building”). All capitalized terms herein are as defined in the Lease. 
 2. Pursuant to the Lease, Landlord and Tenant agreed to and do hereby confirm the following matters as of the Lease: 
  

	 	a.	the date of the First Expansion Date is                 ; 

 

	 	b.	the number of rentable square feet of the Premises is                 ;

  

	 	c.	Tenant’s Pro Rata Share (Operating Expenses) is                 %; and

  

	 	d.	Tenant’s Pro Rata Share (Real Estate Taxes) is                 %.

 3. Tenant confirms that: 
  

	 	a.	it has accepted possession of the First Expansion Space as provided in the Third Amendment; 

 

	 	b.	Landlord is not required to perform any work or furnish any improvements to the First Expansion Space under the Third Amendment; 

 

	 	c.	Landlord has fulfilled all of its obligations under the Lease as of the date hereof; 

 

	 	d.	the Lease is in full force and effect and has not been modified, altered, or amended, except as follows:
                                         
       ; and 

  

	 	e.	there are no set-offs or credits against Rent, and no Security Deposit or prepaid Rent has been paid except as provided by the Lease. 

4. The provisions of this Declaration Dates shall inure to the benefit of, or bind, as the case may require, the parties and their
respective successors and assigns, and to all mortgagees of the Building, subject to the restrictions on assignment and subleasing contained in the Lease, and are hereby attached to and made a part of this Lease. 

  
 10 

 
					
	LANDLORD:
	
	EOS ACQUISITION I LLC, a Delaware limited liability company
		
	By:	 	KBS Capital Advisors, LLC, a Delaware limited liability company, its authorized agent
			
		 	By:	 	  

		 		 	Robin A. Burke
		 		 	Senior Vice President
		
	TENANT:	 	
	
	SALIX PHARMACEUTICALS, INC., a California corporation
			
		 	By:	 	  

					
		 	Name:	 	  

					
		 	Title:	 	  

  
 11 

 EXHIBIT C 
 FOURTH FLOOR OFFER SPACE 
 

 

  
 12Amended and Restated Manufacturing and Supply Agreement

 Exhibit 10.85 
 Portions of this exhibit marked [*] are requested to be treated confidentially. 

EXECUTION VERSION 

AMENDED AND RESTATED MANUFACTURING AND SUPPLY AGREEMENT 
 between 
 SALIX PHARMACEUTICALS, INC. 

and 

GLENMARK PHARMACEUTICALS LTD. 
 Dated as of July 18, 2011 

 TABLE OF CONTENTS 

 

							
	 ARTICLE I. DEFINITIONS
	  	 	1	  
		
	 ARTICLE II. MANUFACTURING
	  	 	10	  
	2.1	 	Purchase and Supply Obligations	  	 	10	  
	2.2	 	Forecasting, Order and Delivery of Compound	  	 	10	  
	2.3	 	Raw Materials	  	 	12	  
	2.4	 	Invoice and Payment	  	 	13	  
	2.5	 	Price	  	 	13	  
	2.6	 	Warranty	  	 	14	  
	2.7	 	Failure or Inability to Supply Compound	  	 	15	  
	2.8	 	Limitations of Current Capacity	  	 	17	  
	2.9	 	Costs and Expenses	  	 	19	  
	2.10	 	Amendment of Specifications	  	 	19	  
	2.11	 	Quality Agreement	  	 	20	  
	2.12	 	Quality Control Analyses and Release	  	 	20	  
	2.13	 	Maintenance of Facilities and Compound Equipment	  	 	20	  
	2.14	 	Regulatory Cooperation of Glenmark	  	 	21	  
	2.15	 	Inspection by Salix	  	 	21	  
	2.16	 	Notification of Regulatory Inspections; Communications	  	 	22	  
	2.17	 	Recalls and Withdrawals	  	 	22	  
	2.18	 	Compliance with Applicable Laws	  	 	22	  
	2.19	 	Retention of Manufacturing Records and Samples	  	 	22	  
	2.20	 	No Other Supply	  	 	23	  
	2.21	 	Shortages	  	 	24	  
	2.22	 	Second Source	  	 	24	  
		
	 ARTICLE III. GLOBAL COORDINATION
	  	 	24	  
	3.1	 	Global Cooperation and Coordination	  	 	24	  
	3.2	 	Consultation	  	 	25	  
	3.3	 	Regulatory Matters	  	 	25	  
	3.4	 	Trademarks	  	 	27	  
		
	 ARTICLE IV. INTELLECTUAL PROPERTY
	  	 	27	  
	4.1	 	Ownership	  	 	27	  
	4.2	 	Patent Maintenance and Prosecution	  	 	28	  
	4.3	 	Enforcement of Invention Patents	  	 	31	  
	4.4	 	Third Person Litigation	  	 	32	  
	4.5	 	Third Party Licenses	  	 	33	  
		
	 ARTICLE V. REPRESENTATIONS AND WARRANTIES; COVENANTS
	  	 	33	  
	5.1	 	Representations and Warranties of Each Party	  	 	33	  
	5.2	 	Additional Warranties and Covenants of Glenmark	  	 	34	  
	5.3	 	Disclaimer of Other Warranties	  	 	34	  

  
 i 

							
	 ARTICLE VI. CONFIDENTIALITY
	  	 	34	  
	6.1	 	Confidential Information	  	 	34	  
	6.2	 	Exceptions to Confidentiality	  	 	35	  
	6.3	 	Disclosure	  	 	35	  
	6.4	 	Notification	  	 	36	  
	6.5	 	Remedies	  	 	36	  
	6.6	 	Use of Names	  	 	36	  
	6.7	 	Press Releases	  	 	36	  
		
	 ARTICLE VII. TERM AND TERMINATION
	  	 	36	  
	7.1	 	Term	  	 	36	  
	7.2	 	Termination	  	 	37	  
	7.3	 	Effect of Expiration or Termination	  	 	38	  
		
	 ARTICLE VIII. INDEMNIFICATION
	  	 	39	  
	8.1	 	Glenmark Indemnification	  	 	39	  
	8.2	 	Salix Indemnification	  	 	39	  
	8.3	 	Indemnification Procedure	  	 	40	  
	8.4	 	Insurance	  	 	42	  
	8.5	 	Limitation on Damages	  	 	42	  
		
	 ARTICLE IX. MISCELLANEOUS
	  	 	43	  
	9.1	 	Notices	  	 	43	  
	9.2	 	Force Majeure	  	 	44	  
	9.3	 	Entire Agreement; Amendment	  	 	45	  
	9.4	 	Further Assurances	  	 	45	  
	9.5	 	Successors and Assigns	  	 	45	  
	9.6	 	Dispute Resolution	  	 	45	  
	9.7	 	Governing Law; Jurisdiction; Venue; Service	  	 	46	  
	9.8	 	Third Party Beneficiaries	  	 	46	  
	9.9	 	Export Control	  	 	47	  
	9.10	 	Assignment	  	 	47	  
	9.11	 	Waiver	  	 	47	  
	9.12	 	Severability	  	 	48	  
	9.13	 	Independent Contractors	  	 	48	  
	9.14	 	Construction	  	 	48	  
	9.15	 	Remedies	  	 	48	  
	9.16	 	Counterparts; Facsimile Execution	  	 	48	  
	9.17	 	English Language	  	 	49	  
	9.18	 	Attorneys’ Fees	  	 	49	  

 Schedules and Exhibits 
  

			
	Schedule 1.5	  	Agreed Scale-Up Plan
	Schedule 1.24	  	Current Capacity
	Schedule 1.37	  	Fully-Allocated Manufacturing Costs
	Schedule 1.46	  	Glenmark Territory

  
 ii 

			
	Schedule 1.89	  	Specifications
	Schedule 2.2(c)	  	Full Production Lot Size
	Schedule 2.5(b)	  	Compensation to Glenmark for Use of Third Party Manufacturer
	Schedule 2.8(f)	  	Napo-Provided Equipment Usage

  
 iii

 This AMENDED AND RESTATED MANUFACTURING AND SUPPLY AGREEMENT (this
“Agreement”), dated as of July 18, 2011 (the “Amendment Effective Date”), is made by and between Salix Pharmaceuticals, Inc., a California corporation (“Salix”), and Glenmark Pharmaceuticals
Ltd., a corporation organized under the laws of India (“Glenmark”). Salix and Glenmark are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

RECITALS 

WHEREAS, the Parties previously entered into a Manufacturing and Supply Agreement, dated December 9, 2008 (the
“Original Agreement”), providing for Glenmark, either itself or through its Affiliate (as defined below) Glenmark Generics Ltd., to manufacture and supply Compound (as defined below) to Salix; and 

WHEREAS, the Parties now desire to amend and restate the Original Agreement as set forth in this Agreement so as to reflect new
terms agreed by the Parties; 
 NOW, THEREFORE, in consideration of the foregoing premises, the mutual promises and
covenants of the Parties contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

ARTICLE I. DEFINITIONS 
 As used herein, the following terms shall have the following meanings: 
 1.1
“Actual Cost” has the meaning set forth in Section 0. 
 1.2 “Advance Agreement” has the
meaning set forth in Section 9.3(b). 
 1.3 “Affiliate” of a Person means any other Person that directly,
or indirectly through one or more intermediaries, controls, is controlled by or is under common control with, such first Person. “Control” and, with correlative meanings, the terms “controlled by” and “under
common control with”, means to possess the power to direct the management or policies of a Person, whether through ownership of voting securities or by contract or otherwise. 

1.4 “Agreed Scale-Up Equipment” has the meaning set forth in Section 2.8(b). 

1.5 “Agreed Scale-Up Plan” means the plan for the expansion of Current Capacity set forth in Schedule 1.5.

 1.6 “Agreement” has the meaning set forth in the preamble hereto. 

1.7 “Amendment Effective Date” has the meaning set forth in the preamble hereto. 

 1.8 “Ankleshwar Facility” means the Manufacturing facility of
Glenmark’s Affiliate, Glenmark Generics Ltd., located at 3109, GIDC Industrial Estate, Ankleshwar 393 002, Gujarat, India. 

1.9 “Applicable Law” means applicable laws, rules and regulations, including any rules, regulations, guidelines or other
requirements of Regulatory Authorities, that may be in effect from time to time. 
 1.10 “Augmented Capacity”
means a yearly rate of maximum production, using commercially reasonable procedures and levels of effort, of the Compound pursuant to the Manufacturing process equal to the Current Capacity as changed, beginning with the implementation of the Agreed
Scale-Up Plan from time to time thereafter, by the implementation of the Agreed Scale-Up Plan. Augmented Capacity resulting from any Supplement Scale-Up Plan shall be as agreed by the Parties in connection with their agreement to the Supplement
Scale-Up Plan. The Parties shall determine the Augmented Capacity as in effect from time to time in good faith by mutual agreement. In the event the Parties are at any time unable to reach agreement as to the Augmented Capacity, then either Party
may, by notice to the other, refer the matter for final resolution to a mutually agreed technical expert who has expertise in determining plant capacity for pharmaceutical manufacturing facilities and who has no current or prior affiliation with
either Party (the “Technical Arbitrator”). The Technical Arbitrator shall make the determination of the Augmented Capacity, which shall be final and binding on the Parties, based on simultaneous written submissions from the Parties
and responses to any supplemental written questions the Technical Arbitrator may deem necessary to determine the Augmented Capacity. In the event the Parties cannot agree on a Technical Arbitrator within ten (10) days of the date of the notice
of referral of the determination of Augmented Capacity to a Technical Arbitrator, then each Party shall select an independent expert and the two independent experts so selected by the Parties shall select the Technical Arbitrator. The two
independent experts appointed by the Parties pursuant to the preceding sentence shall have no role in the arbitration other than to select the Technical Arbitrator. 
 1.11 “Aurangabad Facility” means Glenmark’s Manufacturing facility at Plot No. B-25, Five Star MIDC, Shendra, Aurangabad, Maharashtra, India. 

1.12 “Calendar Year” means each successive period of twelve (12) consecutive calendar months commencing on
January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Amendment Effective Date and end on December 31, 2011, and the last Calendar Year of the Term shall commence on January 1
of the year in which the Term ends and end on the last day of the Term. 
 1.13 “Certificate of Analysis” has
the meaning set forth in the Quality Agreement. 

  
 2 

 1.14 “Certificate of Compliance” has the meaning set forth in the Quality
Agreement. 
 1.15 “CMC Data” means the chemistry, manufacturing and controls data required by Applicable Law
to be included in a New Drug Application (as defined in the FFDCA and the regulations promulgated thereunder) for a Product or in any other Marketing Authorization outside the United States. 

1.16 “Commitment Fee” has the meaning set forth in Section 2.8(e). 

1.17 “Compound” means oligomeric proanthocyanidin (OPC) of varying chain lengths with an average molecular weight of
approximately 2000 daltons (Crofelemer) meeting the Specifications. 
 1.18 “Compound Equipment” means the
Napo-Provided Equipment, the Agreed Scale-Up Equipment, and any Supplement Scale-Up Equipment. 
 1.19 “Compound
Invention Patents” has the meaning set forth in Section 4.2(a)(i). 
 1.20 “Compound Inventions”
means any and all Inventions relating to the Compound or any derivatives thereof or other compounds related thereto, that are conceived, discovered, developed or otherwise made, solely by a Party or jointly by or on behalf of the Parties as a result
of or in connection with this Agreement, but excluding the Glenmark Inventions. 
 1.21 “Confidential
Information” means any and all information or material that, at any time before or after the Amendment Effective Date, has been or is provided or communicated to the Receiving Party by or on behalf of the Disclosing Party pursuant to this
Agreement or in connection with the transactions contemplated hereby or any discussions or negotiations with respect thereto; any data, ideas, concepts or techniques contained therein; and any modifications thereof or derivations therefrom.
Confidential Information may be disclosed either orally, visually, electronically, in writing, by delivery of materials containing Confidential Information or in any other form now known or hereafter invented; provided, however, that
notwithstanding the Party that disclosed such information or material, (a) all information and materials regarding the Compound, including the Specifications, Salix Information, and Compound Inventions, shall be Confidential Information of
Salix and not the Confidential Information of Glenmark, and Salix will be deemed to be the Disclosing Party, and Glenmark will be deemed to be the Receiving Party, with respect thereto, and (b) Glenmark Information shall be Confidential
Information of Glenmark and not the Confidential Information of Salix, and Glenmark will be deemed to be the Disclosing Party, and Salix will be deemed to be the Receiving Party, with respect thereto. 

1.22 “Courts” has the meaning set forth in Section 9.7(b). 

  
 3 

 1.23 “CPL” means crude plant latex of croton lechleri that meets the
Specifications. 
 1.24 “Current Capacity” means the capacity of Glenmark’s equipment and processes to
Manufacture the Compound on an annual basis that was in place at the Ankleshwar Facility as of the Effective Date, as set forth on Schedule 1.24, and that continues to be the capacity of Glenmark’s equipment and processes to Manufacture
the Compound on an annual basis as of the Amendment Effective Date. 
 1.25 “Disclosing Party” means the Party
disclosing Confidential Information. 
 1.26 “Dispute” has the meaning set forth in Section 9.6.

 1.27 “Drug Master File” means any drug master file filed with the FDA with respect to a Product, and any
equivalent filing in other countries or regulatory jurisdictions. 
 1.28 “Effective Date” has the meaning
given to such term in the Original Agreement. 
 1.29 “European Union” or “EU” means the
economic, scientific and political organization of member states of the European Union, and which, as of the Amendment Effective Date, consists of Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece,
Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom, and that certain portion of Cyprus included in such organization. 

1.30 “Excluded Lists” means the United States Department of Health and Human Service’s List of Excluded
Individuals/Entities and the General Services Administration’s Lists of Parties Excluded from Federal Procurement and Non-Procurement Programs. 
 1.31 “Exploit” means to make, have made, import, use, sell, offer for sale or otherwise dispose of a compound, product or process, including all discovery, research, development,
commercialization, registration, modification, enhancement, improvement, Manufacture, storage, formulation, optimization, exportation, transportation, distribution, promotion and marketing of such compound, product or process. 

1.32 “Facilities” means the Ankleshwar Facility and the Aurangabad Facility, together, and “Facility”
means either one of them. 
 1.33 “FDA” means the United States Food and Drug Administration and any successor
agency thereto. 

  
 4 

 1.34 “FFDCA” means the United States Federal Food, Drug, and Cosmetic Act,
as amended. 
 1.35 “Firm Forecast” has the meaning set forth in Section 2.2(b). 

1.36 “Forecast” has the meaning set forth in Section 2.2(b). 

1.37 “Fully-Allocated Manufacturing Cost” or “FAMC” has the meaning set forth in Schedule 1.37.

 1.38 “Glenmark” has the meaning set forth in the preamble hereto. 

1.39 “Glenmark Activities” has the meaning set forth in Section 2.8(f). 

1.40 “Glenmark Indemnified Parties” has the meaning set forth in Section 8.2. 

1.41 “Glenmark Information” means all technical, scientific and other know-how and information, trade secrets,
knowledge, technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, technical assistance, designs, assembly procedures, specifications, assays, test methods, analytical methods, and other material or
information owned or controlled by Glenmark and its Affiliates and necessary or useful for the Manufacture of the Compound, excluding Glenmark Inventions. 
 1.42 “Glenmark Invention Patents” has the meaning set forth in Section 4.2(b)(i). 
 1.43 “Glenmark Inventions” has the meaning set forth in Section 4.1(b). 
 1.44 “Glenmark Policies” has the meaning set forth in Section 8.4(b). 
 1.45 “Glenmark-Supplied Material” means all ingredients, raw materials, packaging and labeling components, and all other supplies of any kind used in connection with Manufacturing the
Compound, excluding the Salix-Supplied Material. 
 1.46 “Glenmark Territory” shall mean the countries set
forth on Schedule 1.46. 
 1.47 “GMP” means current good manufacturing practices as required under the
FFDCA and as set forth by the FDA in regulations promulgated at 21 C.F.R. Parts 210 and 211, and in applicable FDA guidance and policy documents. 
 1.48 “Hatch-Waxman Act” means the Drug Price Competition and Patent Term Restoration Act of 1984, as amended. 

  
 5 

 1.49 “Indemnification Claim Notice” has the meaning set forth in
Section 8.3(a). 
 1.50 “Indemnified Party” has the meaning set forth in Section 8.3(a). 

1.51 “Indemnifying Party” has the meaning set forth in Section 8.3(a). 

1.52 “Informational Forecast” has the meaning set forth in Section 2.2(a). 

1.53 “Invention” means any discovery, improvement, process, formula, data, invention, know-how, trade secret, procedure,
device, or other intellectual property, whether or not patentable, including any enhancement in the manufacture, formulation, ingredients, preparation, presentation, means of delivery, dosage or packaging of a compound or product or any discovery or
development of a new indication for a compound or product. 
 1.54 “Joint Invention Patents” has the meaning
set forth in Section 4.2(c)(i). 
 1.55 “Joint Inventions” means any manufacturing technique, process or
Compound derivative that is not derived from or based on the Specifications, any Salix Information, Compound Invention or Glenmark Information that is conceived, discovered, developed or otherwise made, jointly by or on behalf of the Parties as a
result of or in connection with this Agreement, but excluding the Glenmark Inventions. 
 1.56 “Launch Date”
means the first date on which Salix anticipates requiring supply of Compound hereunder in order to make Product available for commercial sale or distribution. 
 1.57 “Losses” has the meaning set forth in Section 8.1. 

1.58 “Manufacture” and “Manufacturing” means (a) the manufacturing, processing, formulating,
packaging, labeling, holding, storage, warehousing, and quality control testing of a pharmaceutical product or compound and (b) the holding, storage or warehousing of raw materials, finished product or work in process. 

1.59 “Marketing Authorization” means an approved New Drug Application as defined in the FFDCA and the regulations
promulgated thereunder, or any corresponding foreign application, registration or certification, necessary or reasonably useful to market any Product in a country or regulatory jurisdiction in the Territory other than the United States, including
applicable pricing and reimbursement approvals. 
 1.60 “Material(s)” means the Glenmark-Supplied Material and
the Salix-Supplied Material. 
 1.61 “Napo” means Napo Pharmaceuticals, Inc. 

1.62 “Napo-Glenmark Agreement” means that certain Collaboration Agreement entered into on July 2, 2005, by and
between Glenmark and Napo, as 

  
 6 

 
amended by the First Amendment thereto dated [*], the Second Amendment thereto dated October 26, 2005, the Third Amendment thereto dated [*], the Fourth Amendment thereto dated May 30,
2006, the Fifth Amendment thereto dated December 7, 2008, and clarified by a letter from Glenmark to Napo dated December 9, 2008. Glenmark represents and warrants to Salix that, except for the amendments and letters to which reference is
made in the preceding sentence, there have been no amendments or modifications to the original June 2, 2005 Collaboration Agreement that is referenced in the preceding sentence. 

1.63 “Napo-Provided Equipment” means the required [*], [*] and [*] provided by Napo, at its sole cost and expense, and
used in the Manufacture of Compound as of the Effective Date. 
 1.64 “Original Agreement” has the meaning set
forth in the recitals. 
 1.65 “Other Product Entry” has the meaning set forth in Section 7.2(c)(iii).

 1.66 “Party” and “Parties” has the meaning set forth in the preamble hereto. 

1.67 “Patents” means the Compound Invention Patents, the Glenmark Invention Patents and the Joint Invention Patents.

 1.68 “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability
partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency
of a government. 
 1.69 “Policies” means the Glenmark Policies and the Salix Policies. 

1.70 “Product” means a pharmaceutical product that contains the Compound as an active ingredient. 

1.71 “Purchase Order” means a written purchase order that sets forth, with respect to the period covered thereby,
(a) the quantities of Compound to be delivered by Glenmark to Salix and (b) the required delivery dates therefor. 

1.72 “Purchase Price” has the meaning set forth in Section 0. 

1.73 “Quality Agreement” means the quality assurance agreement to be agreed between the Parties relating to the
Manufacture of the Compound in accordance with Section 2.11, as such agreement shall be amended from time to time. 
 1.74
“Recalls” shall have the meaning set forth in Section 3.3(e). 
 [*] Confidential treatment requested. 

  
 7 

 1.75 “Receiving Party” means the Party receiving Confidential Information.

 1.76 “Recipients” has the meaning set forth in Section 6.1. 

1.77 “Regulatory Approval” means, with respect to any particular country, any and all approvals, licenses, registrations
or authorizations of any Regulatory Authority necessary for the Exploitation of a Product in such country (or, if applicable, the EU), including, where applicable, (a) approval of a Product in such country (or, if applicable, the EU), including
any Marketing Authorization and supplements and amendments thereto; (b) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto); (c) labeling approval; and
(d) technical, medical and scientific licenses. 
 1.78 “Regulatory Authority” means any applicable
supra-national, federal, national, regional, state, provincial or local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the Exploitation of
the Compound or a Product in any country or jurisdiction in the Specified Territory. 
 1.79 “Regulatory
Documentation” means (a) submissions to any Regulatory Authority, including investigational new drug applications, New Drug Applications (as defined in the FFDCA and the regulations promulgated thereunder), Drug Master Files,
correspondence with regulatory agencies (registrations and licenses, regulatory drug lists, advertising and promotion documents), period safety update reports, adverse event files, complaint files and manufacturing records and, if applicable, any
updates or supplements to any of the foregoing, (b) any minutes or contact logs with respect to any telephone conferences conducted with any Regulatory Authority relating to the subject matter described in Section 1.79(a) and (c) any
written correspondence received from any Regulatory Authority. 
 1.80 “Salix” has the meaning set forth in the
preamble hereto. Salix was erroneously identified in the Original Agreement as a Delaware corporation, but it is in fact a California corporation. 
 1.81 “Salix Indemnified Parties” has the meaning set forth in Section 8.1. 
 1.82 “Salix Information” means all technical, scientific and other know-how and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulae,
instructions, skills, techniques, procedures, technical assistance, designs, assembly procedures, specifications, assays, test methods, analytical methods, and other material or information owned or controlled by Salix and its Affiliates and
necessary or useful for the Manufacture of the Compound. 
 1.83 “Salix Policies” has the meaning set forth in
Section 8.4(a). 
 1.84 “Salix-Supplied Material” means the CPL sold by Salix to Glenmark hereunder and
used by Glenmark in connection with Manufacturing the Compound. 

  
 8 

 1.85 “Salix-Supplied Material Cost” means, in respect of any particular
kilogram of Compound, the amount paid by Glenmark to Salix for the Salix-Supplied Material consumed in producing such kilogram of Compound, as reasonably determined by [*]. 
 1.86 “Supplement Scale-Up Equipment” has the meaning set forth in Section 2.8(c). 
 1.87 “Supplement Scale-Up Plan Effective Date” has the meaning set forth in Section 2.8 (c). 
 1.88 “Supplement Scale-Up Plan” means adaptations, scale-ups or improvements to Glenmark’s Manufacturing equipment or processes required in order to satisfy Salix’s anticipated
annual requirements in excess of the then-current Augmented Capacity, but does not include the Agreed Scale-Up Plan. 
 1.89
“Specifications” means, with respect to the Compound, those Compound-related specifications set forth on Schedule 1.89 and, with respect to CPL, those CPL-related specifications set forth on Schedule 1.89, in each case
as the same may be amended from time to time in accordance with the terms hereof. 
 1.90 “Specified Territory”
means the United States, the EU and India, together with such additional countries or territories as may be agreed by the Parties pursuant to written amendment to this Agreement. The Parties agree that upon the proposal by Salix of additional
countries or territories to be included in the definition of “Specified Territory,” they will negotiate in good faith in respect of the inclusion of such additional countries or territories in such definition, including with respect to the
appropriate allocation between the Parties of any additional costs anticipated as a result thereof. 
 1.91 “Technical
Arbitrator” has the meaning set forth in Section 1.10. 
 1.92 “Territory” means the entire
world. 
 1.93 “Term” has the meaning set forth in Section 7.1. 

1.94 “Testing Expert” has the meaning set forth in Section 2.7(d). 

1.95 “Third Party Claim” has the meaning set forth in Section 8.3(b). 

1.96 “Third Party Manufacturer” means any Third Party manufacturer of the Compound designated by Salix, other than an
Affiliate of Glenmark. 
 1.97 “Third Party Manufacturer License” means the license described in Schedule
1.97. 
 1.98 “United States” means the United States of America. 

[*] Confidential treatment requested. 

  
 9 

 ARTICLE II. MANUFACTURING 

2.1 Purchase and Supply Obligations. 
 (a) Subject to the terms and conditions hereof, Glenmark shall Manufacture or have Manufactured by its Affiliate, Glenmark Generics Ltd., and supply to Salix, and Salix shall purchase from Glenmark, such
quantities of Compound as Salix may order pursuant to Purchase Orders in accordance with the terms hereof from time to time during the Term. 
 (b) During the [*] ([*]) years following the first installation of Agreed Scale-Up Equipment and the production of the first trial batch of Compound therefrom, Salix shall order from Glenmark, on an [*]
basis, the lesser of (i) the then-current Augmented Capacity (pro rated and averaged (on the basis of number of days elapsed) as necessary in respect of any partial year) and (ii) [*] percent ([*]%) of Salix’s aggregate
requirements of Compound. For each year in the aforesaid [*] ([*])-year period, Salix shall provide to Glenmark, within [*] ([*]) [*] after the end of such year, a certification that it has ordered the required portion of its requirements of
Compound for that year from Glenmark. 
 2.2 Forecasting, Order and Delivery of Compound. 

(a) At least [*] ([*]) days prior to the first day of each Calendar Year during the Term commencing with the Calendar Year in which the
Launch Date is anticipated to occur, Salix shall deliver to Glenmark a written good faith forecast estimating, on a [*] basis, the quantities of Compound that Salix expects to purchase from Glenmark during such Calendar Year (each, an
“Informational Forecast”). Each Informational Forecast shall be non-binding and shall be used by Glenmark for planning purposes only. 
 (b) On or before the fifteenth (15th) day of each month, commencing at least [*] ([*]) months prior to the month in which the Launch Date is anticipated to occur, Salix shall deliver to Glenmark a
written good faith forecast estimating the quantities of Compound that Salix expects to purchase from Glenmark for each month during the following [*] ([*]) months (each, a “Forecast”). The [*] ([*]) months of each Forecast shall be
a “Firm Forecast”. Except as provided in Section 2.2(c), each Forecast shall be non-binding and shall be used by Glenmark for planning purposes only. 
 (c) Without duplication of any previously delivered Purchase Order, each Firm Forecast shall be accompanied by a Purchase Order for Compound to be delivered to Salix during each of the first [*] ([*])
months, respectively, set forth in 
 [*] Confidential treatment requested. 

  
 10 

 such Firm Forecast. The quantity of Compound specified in any Purchase Order for delivery in any month
(i) shall be in multiples of the full production lots of Compound set forth on Schedule 2.2(c) and (ii) shall not be (A) less than [*] percent ([*]%) nor more than [*] percent ([*]%) of the quantities specified in any previous
Firm Forecast applicable to such month or (B) such that it would require Glenmark to Manufacture and supply to Salix in respect of the month to which it relates more than [*] ([*]) of the then-current Augmented Capacity. In no event shall the
delivery date of Compound for any Purchase Order be less than [*] ([*]) months from the date of the Purchase Order; provided, however, that such period shall be shortened to [*] ([*]) months so long as Salix has fulfilled its obligations
under Section 2.3(b) to provide to Glenmark the Salix-Supplied Material in respect of such Purchase Order. 
 (d) Glenmark
shall have [*] ([*]) business days following receipt of any Purchase Order submitted by Salix to reject such Purchase Order; otherwise the Purchase Order shall be deemed for all purposes of this Agreement to have been accepted by Glenmark. Glenmark
shall not have the right to reject any Purchase Order submitted by Salix that complies with the requirements of Section 2.2(c). Glenmark may, in its discretion, reject any Purchase Order that is not in compliance with the provisions of
Section 2.2(c). Any such rejection must be in the form of a writing delivered to Salix at the address specified on the Purchase Order on or before the end of the [*] ([*]) business day period contemplated by the first sentence of this
Section 2.2(d). Glenmark may in its discretion accept a Purchase Order in advance of the expiration of the [*] ([*]) business day period contemplated by the first sentence of this Section 2.2(d) by delivery of a writing to such effect to
Salix, in which case Glenmark shall be deemed to have waived its right to thereafter reject such Purchase Order. 
 (e) Salix
shall be obligated to purchase, and Glenmark shall be obligated to deliver by the required delivery date set forth therein, such quantities of Compound as are set forth in each accepted Purchase Order. 

(f) In the event that the terms of any Purchase Order are not consistent with or are in addition to the terms of this Agreement, the terms
of this Agreement shall prevail. 
 (g) Glenmark shall deliver the quantities of Compound set forth in each accepted Purchase
Order by the required delivery date set forth in such Purchase Order [*] (as defined in Incoterms 2010) the port of entry in any Specified Territory (or, in the case of the EU, any member state of the EU), but expressly not including India,
designated by Salix; provided, however, that (i) Glenmark shall only engage such carriage, insurance or other providers in connection with such delivery as are designated by Salix in the applicable Purchase Order, (ii) [*] shall
bear costs and expenses for (A) carriage and insurance of the Compound from the Facility and (B) clearance of Compound through customs in the destination country and (iii) in the event any claim 

[*] Confidential treatment requested. 

  
 11 

 arises against any such carriage, insurance or other provider, Glenmark, as promptly as possible, shall
assign such claim to Salix. All Compound shall be labeled in accordance with Applicable Law and packed for shipping in accordance with packing instructions provided by Salix. Title to and risk of loss of Compound shall pass to Salix at the time of
delivery. 
 (h) Each delivery of Compound shall be accompanied by (i) a Certificate of Analysis, (ii) a Certificate of
Compliance, (iii) such other documents as may be required pursuant to the Quality Agreement, and (iv) documentation necessary for the sale or import of the Compound. 
 2.3 Raw Materials. 
 (a) In any given month, Glenmark shall maintain an
inventory of Materials in sufficient quantities, and shall use its commercially reasonable efforts, to supply Salix with quantities of Compound that are up to [*] percent ([*]%) of the quantities specified in any Firm Forecast applicable to such
month. 
 (b) In connection with the delivery of each Firm Forecast by Salix to Glenmark, Salix shall sell and deliver to
Glenmark, [*] (Incoterms 2010) such Facility as Glenmark may specify or on such other terms as the Parties may from time to time agree in writing, such quantities of Salix-Supplied Material as are necessary for Manufacture of Compound in accordance
with the Firm Forecast. Such Salix-Supplied Material shall be sold by Salix to Glenmark and delivered on a schedule consistent with Glenmark’s need for Salix-Supplied Material in order to meet the Firm Forecast. The Salix-Supplied Material
shall be sold by Salix to Glenmark, and purchased by Glenmark from Salix, for a purchase price equal to [*] (including [*], and [*]) [*]. All Salix-Supplied Material shall be labeled in accordance with Applicable Law and packed for shipping in
accordance with packing instructions provided by Glenmark. Title to and risk of loss of Salix-Supplied Material shall pass to Glenmark at the time of delivery. 
 (c) The price to be paid by Glenmark for Salix-Supplied Material is exclusive of all value added or other similar taxes payable to any taxing authority in respect of or arising from the purchase of the
Salix-Supplied Materials by Glenmark or the payment by Glenmark of the purchase price for such Salix-Supplied Material so long as any importation of the Salix-Supplied Material into India that may occur is effected by Glenmark. All such taxes shall
be borne exclusively by [*] without recourse to [*] or, if paid by [*], refunded by [*] to [*] promptly upon [*] receipt of [*] invoice for the amount of such taxes. 
 (d) Salix promptly shall invoice Glenmark for all quantities of Salix-Supplied Material delivered in accordance herewith. Payment with respect to Salix-Supplied Material delivered shall be due [*] ([*])
days from the date of invoice to Glenmark. Payment of invoices shall be made by wire transfer to an account designated in writing by Salix in United States Dollars. 
 [*] Confidential treatment requested. 

  
 12 

 (e) Glenmark shall use the Salix-Supplied Material solely for the purpose of Manufacturing
the Compound for supply to Salix. 
 (f) In the event Salix fails to deliver Salix-Supplied Material in quantities and quality
necessary for Glenmark to Manufacture Compound in accordance with the applicable Purchase Order, such failure shall be deemed a force majeure event for which Glenmark’s obligation to supply to Salix shall be excused until such force majeure
event has been corrected or eliminated. 
 (g) Each Party shall be responsible for auditing and qualifying its respective third
party supplier(s) of Materials and obtaining supplies of Materials in accordance with the applicable Specifications. All Materials shall conform to the applicable Specifications and any applicable Drug Master File, as further referenced in any
applicable Regulatory Documentation. 
 2.4 Invoice and Payment. Glenmark promptly shall invoice Salix for all quantities
of Compound delivered in accordance herewith. Payment with respect to Compound delivered shall be due [*] ([*]) days from the date of invoice to Salix; provided that if Salix rejects such Compound pursuant to Section 2.7, then payment
shall be due within [*] ([*]) days after receipt by Salix of notice from the Testing Expert that the invoiced Compound is conforming or, subject to Section 2.7, receipt by Salix of replacement Compound, as the case may be; provided
further, if Salix disputes any portion of an invoice, it shall pay the undisputed portion and shall provide Glenmark with written notice of the disputed portion and its reasons therefor, and Salix shall not be obligated to pay such disputed portion.
The Parties shall use good faith efforts to resolve any such disputes promptly. In the event of any inconsistency between an invoice and this Agreement, the terms of this Agreement shall control. Payment of invoices shall be made by wire transfer to
an account designated in writing by Glenmark in United States Dollars. If any currency conversion shall be required in connection with any payment hereunder, such conversion shall be made each calendar quarter using an exchange rate that is the
arithmetic average of the daily exchange rates (obtained as described below) during such calendar quarter. Each daily exchange rate shall be obtained from The Wall Street Journal, Eastern United States Edition, or, if not so available, as
otherwise agreed by the Parties. 
 2.5 Price. 
 (a) The purchase price per kilogram (the “Purchase Price”) for all Compound delivered hereunder shall equal the sum of (i) [*] plus [*] ([*]%) plus (ii) [*]. Along with each
acceptance of a Purchase 
 [*] Confidential treatment requested. 

  
 13 

 Order pursuant to Section 2.2(d), Glenmark shall also confirm the Purchase Price applicable for such
Purchase Order, based on the formula set forth in the preceding sentence. If Glenmark fails to confirm the Purchase Price for any Purchase Order, the Purchase Price for such Purchase Order shall be [*]. No later than [*] ([*]) days following each
anniversary of the first day of the month in which Glenmark commences commercial supply to Salix, Glenmark shall calculate the sum of (i) its actual Fully-Allocated Manufacturing Cost of manufacturing Compound supplied to Salix in the [*] (the
“Actual Cost”). If the Purchase Price paid by Salix for Compound is within [*] ([*]%) of the Actual Cost, then no reconciliation of the Purchase Price will be made between the Parties. If the Purchase Price paid by Salix for
Compound is greater than the Actual Cost by more than [*] percent ([*]%), then Glenmark shall reimburse Salix for such amount in excess of [*] percent ([*]%) within [*] ([*]) days of such determination. If the Purchase Price paid by Salix for
Compound is less than the Actual Cost by more than [*] percent ([*]%), then Salix shall reimburse Glenmark for such amount in excess of [*] percent ([*]%) within [*] ([*]) days of such determination. 

(a) Glenmark shall provide Salix with access to such books, records, and financial and other information, including in
respect of the details of its arrangements with third parties for the supply of Materials, as Salix may reasonably request in order to establish that the Purchase Price for Compound supplied hereunder is in compliance with the provisions of Section
0. 
 (b) The Parties acknowledge that Glenmark has invested significant resources in developing and optimizing
the manufacturing process for the Manufacture of Compound. In the event that Salix uses a Third Party Manufacturer, Salix shall provide compensation to Glenmark as set forth in Schedule 2.5(b), subject to all of the limitations set forth in
such Schedule including the limitation with respect to the [*] ([*]) year duration of such obligations. 
 2.6 Warranty.
In connection with each delivery of Compound to Salix hereunder, Glenmark hereby represents and warrants to Salix as of the date of the delivery of such Compound to Salix as follows: (a) such Compound is in conformity with the Specifications
and the Certificate of Analysis therefor provided pursuant to Section 2.2(h); (b) such Compound has been Manufactured in conformance with GMP, all other Applicable Law, this Agreement and the Quality Agreement; (c) title to such
Compound will pass to Salix free and clear of any security interest, lien or other encumbrance; (d) such Compound has been Manufactured at the Facility and those portions of the Facility used in the Manufacture of the Compound are in compliance
with all Applicable Law at the time of such Manufacture (including applicable GMP and inspection requirements of FDA and other Regulatory Authorities); (e) the expiration date of such Compound is no earlier than [*] ([*]) months after the date
of delivery thereof (or such longer period after the date of delivery thereof as may be supported by ongoing stability studies, it being acknowledged that a [*] ([*]) month period must be allowed for packaging and shipment); (f) such Compound
has not been adulterated (as such term is 
 [*] Confidential treatment requested. 

  
 14 

 defined in the FFDCA) at the time of shipment by Glenmark from the Facility; (g) such Compound may be
introduced into interstate commerce pursuant to the FFDCA and similar provisions of other Applicable Law in the Specified Territory; and (h) neither Glenmark nor any of its Affiliates has been debarred or is subject to debarment pursuant to
Section 306 of the FFDCA or any similar law in any country in the Specified Territory or listed on either Excluded List or any similar list in any country in the Specified Territory; provided that, with respect to any such similar laws
or lists in any country in the Specified Territory other than the United States, Salix has identified for Glenmark with specificity such law or list. 
 2.7 Failure or Inability to Supply Compound. 
 (a) In the event that
Glenmark, at any time during the Term, shall have reason to believe that it will be unable to supply Salix with the full quantity of Compound forecasted to be ordered by Salix or the full quantity of Compound ordered by Salix pursuant to a Purchase
Order submitted by Salix, in each case in a timely manner and in conformity with the warranties set forth in Section 2.6, Glenmark shall promptly notify Salix thereof. Promptly thereafter, the Parties shall meet to discuss how Salix shall
obtain such full quantity of conforming Compound. Compliance by Glenmark with this Section 2.7(a) shall not relieve Glenmark of any other obligation or liability under this Agreement, including any obligation or liability under
Section 2.7(b) or 2.7(c). 
 (b) Subject to Section 2.7(f), if Glenmark fails to deliver the full quantity of Compound
specified in an accepted Purchase Order by [*] ([*]) days after the required delivery date specified therein and in conformity with the warranty set forth in Section 2.6, then Salix may, at its option, (i) cancel all or any portion of such
Purchase Order, in which event Salix shall have no liability with respect to the portion of such Purchase Order so cancelled, or (ii) accept late delivery of all or any portion of the Compound specified in such Purchase Order. 

(c) Subject to Section 2.7(f), if Glenmark fails to deliver the full quantity of Compound specified in an accepted Purchase Order by
[*] ([*]) days after the required delivery date specified therein and in conformity with the warranty set forth in Section 2.6, then Salix may, at its option, (i) accept late delivery of all or any portion of the Compound specified in such
Purchase Order, (ii) terminate its obligations under Section 2.1(b) by written notice to Glenmark, or (iii) provide written notice to Glenmark of its intention to qualify a Third Party Manufacturer for the Compound, in which event
Glenmark shall use its commercially reasonable efforts promptly to assist Salix to qualify such Third Party Manufacturer designated by Salix to Manufacture such Compound and provide to such Third Party Manufacturer such technical assistance as Salix
may reasonably request and such Third Party Manufacturer may reasonably require in order to Manufacture the Compound, all without charge to Salix except that Salix shall be responsible for the out of pocket expenses incurred by Glenmark in providing
such technical assistance. The technical assistance contemplated by the preceding sentence shall not, unless otherwise agreed by Glenmark, be for more than [*] (equal to [*] work 
 [*] Confidential treatment requested. 

  
 15 

 
hours each). Glenmark shall also promptly grant to such Third Party Manufacturer a Third Party Manufacturer License, provided that Salix shall compensate Glenmark in the manner set forth
in Schedule 2.5(b), subject to all of the limitations set forth in such Schedule including the limitation with respect to the [*] ([*]) year duration of such obligations and Schedule 1.37, Section III. 

(d) In the event that Salix determines, within [*] ([*]) days after delivery thereof by Glenmark (or within [*] ([*]) days after discovery
of any non-conformity that could not reasonably have been detected by a customary inspection on delivery, so long as such discovery is during the production of Product, but in no event more than [*] ([*]) months after delivery of Compound by
Glenmark), that any Compound supplied by Glenmark does not conform to the warranties set forth in Section 2.6, Salix shall give Glenmark notice thereof (including a sample of such Compound, if applicable). Glenmark shall undertake appropriate
evaluation of any such sample and shall notify Salix whether it has confirmed such nonconformity within [*] ([*]) days after receipt of such notice from Salix. If Glenmark notifies Salix that it has not confirmed such nonconformity, then the Parties
shall submit the dispute to an independent testing laboratory or other appropriate expert mutually acceptable to the Parties (the “Testing Expert”) for evaluation. Both Parties shall cooperate with the Testing Expert’s
reasonable requests for assistance in connection with its evaluation hereunder. The findings of the Testing Expert shall be binding on the Parties, absent manifest error. The expenses of the Testing Expert shall be borne by Glenmark if the testing
confirms the nonconformity and otherwise by Salix. If the Testing Expert or Glenmark confirms that a lot of Compound does not conform to the warranties set forth in Section 2.6, then Glenmark, at Salix’s option, promptly shall
(A) supply Salix with a conforming quantity of Compound at Glenmark’s expense or (B) reimburse Salix for the Purchase Price paid by Salix with respect to such non-conforming Compound if already paid. In addition, Glenmark promptly
shall reimburse Salix for all costs incurred by Salix with respect to such non-conforming Compound. Salix shall have the right to offset any such costs against any payments owed by Salix to Glenmark under this Agreement. Glenmark immediately shall
notify Salix if at any time it discovers that any Compound delivered hereunder does not conform to the Specifications. Notwithstanding any other provision of this Section 2.7(d), Glenmark shall have no liability hereunder to the extent any such
liability is attributable to (i) a failure of Salix-Supplied Material to conform to 
 [*] Confidential treatment requested. 

  
 16 

 
applicable Specifications as of its time of delivery to Glenmark or (ii) Salix-Supplied Material having been adulterated (as such term is defined in the FFDCA) prior to the time of delivery
to Glenmark. 
 (e) Subject to Salix’s right to indemnification under Section 8.1, the rights and remedies provided in
this Section 2.7 shall be cumulative and shall be Salix’s sole and exclusive remedy with respect to Glenmark’s (i) failure to supply Compound that conforms to the warranties set forth in Section 2.6 or (ii) inability to
supply Compound pursuant to any accepted Purchase Order. 
 (f) The rights and remedies provided in Sections 2.7(b) and
(c) shall be subject to Salix fulfilling its obligations under Section 2.3(b). 
 2.8 Limitations of Current
Capacity. 
 (a) The Parties acknowledge the Current Capacity production constraints of Glenmark, and, subject to
Section 2.8(b), agree that the estimation of the maximum annual quantities of the Compound that Glenmark is capable of delivering to Salix as of the Amendment Effective Date are as set forth on Schedule 1.24. 

(b) In anticipation of Salix’s annual requirements exceeding the amount of Compound permitted by Current Capacity, the Parties have
agreed to the Agreed Scale-Up Plan. Promptly following the Amendment Effective Date, Glenmark shall proceed with the implementation of the Agreed Scale-Up Plan and shall use its commercially reasonable efforts to complete all aspects of the Agreed
Scale-Up Plan not later than [*] from the Amendment Effective Date or any extension that may be mutually agreed by the Parties. [*] shall be solely and exclusively responsible for any and all costs associated with the implementation of the Agreed
Scale-Up Plan, including the purchase and installation of any and all equipment contemplated by the Agreed Scale-up Plan (the “Agreed Scale-up Equipment”). 
 (c) In the event Salix’s annual requirements should at any time during the Term be expected by Salix to exceed the Augmented Capacity then in effect or then expected to be in effect following the
implementation of the Agreed Scale-Up Plan or any prior Supplement Scale-Up Plan to which the Parties may have agreed, then the Parties shall discuss in good faith a Supplement Scale-Up Plan, including allocation of costs for any equipment
contemplated by the Supplement Scale-Up Plan, and how the expected results of the Supplement Scale-Up Plan are to be reflected in Augmented Capacity and its impact on the ability and obligation of Glenmark to supply, and Salix to purchase, Compound
hereunder (the “Supplement Scale-Up Equipment”). Upon agreement of any such Supplement Scale-Up Plan and Salix’s direction to Glenmark to initiate the Supplement Scale-Up Plan, Glenmark agrees to use its commercially reasonable
efforts 
 [*] Confidential treatment requested. 

  
 17 

 
to implement as promptly as possible the Supplement Scale-Up Plan. Until such time as Glenmark has been afforded a reasonable period of time to implement the Supplement Scale-Up Plan (the
“Supplement Scale-Up Plan Effective Date”), Glenmark’s inability to supply Compound in excess of the then-current Augmented Amount shall not be construed as a material breach of this Agreement 

(d) In connection with the implementation of the Agreed Scale-Up Plan or any Supplement Scale-Up Plan, Glenmark shall perform appropriate
testing, consistent with standards and procedures commonly accepted for such purpose in the pharmaceutical industry, to permit the Parties to establish the Augmented Capacity resulting from the Agreed Scale-Up Plan or such Supplement Scale-Up Plan,
as the case may be. Salix shall be entitled to observe, through its designees, any and all such testing and to receive the full and complete results of the same together with any analysis thereof or other information relating thereto that may be
prepared, developed or obtained by Glenmark. 
 (e) In view of the substantial investment to be made by Glenmark towards
implementation of the Agreed Scale-Up Plan pending the determination of the demand for the Compound and in view of the risk associated with the same as it being specifically for the Manufacture of Compound exclusively for Salix, Salix agrees and
undertakes to pay Glenmark a commitment fee in the aggregate amount of twenty one million six hundred thousand United States dollars ($21,600,000) (the “Commitment Fee”). The Commitment Fee shall be payable to Glenmark by Salix in
five equal annual installments ([*]) of four million three hundred twenty thousand United States dollars ($4,320,000) each, the first of such installments to become due on the first anniversary of the Amendment Effective Date and the remaining four
installments each to become due on one of the second through fifth anniversaries of such date. The Advance contemplated by the Advance Agreement shall be applied in accordance with the terms of the Advance Agreement against the amount of each such
installment, with the result that the net amount remaining to be paid by Salix to Glenmark in respect of each such installment shall be one million three hundred twenty thousand United States dollars ($1,320,000). Each such installment amount shall
be payable by Salix to Glenmark within [*] ([*]) days following the date of Salix’s receipt of an invoice from Glenmark for the specified amount. The Commitment Fee is in addition to the Purchase Price payable by Salix to Glenmark for Compound
supplied by Glenmark to Salix hereunder. For the avoidance of doubt, the provisions of this Section 2.8(e) shall terminate upon any termination of this Agreement and Salix shall have no obligation to pay any installment in respect of the
Commitment Fee that has not become due as of the date of such termination. 
 (f) Glenmark shall have the right to use the
Napo-Provided Equipment to (i) carry out any research, development scale-up and other activities relating to the Compound, 
 [*]
Confidential treatment requested. 

  
 18 

 
provided, however, that such usage shall not exceed [*] percent ([*]%) of the Napo-Provided Equipment’s capacity and (ii) subject to Section 2.21, [*], [*] permitted
pursuant to the Napo-Glenmark Agreement (collectively, the “Glenmark Activities”). 
 (g) Except as provided in
Section 2.8(f), Glenmark shall use the Napo-Provided Equipment solely and exclusively for the Manufacture of Compound for supply to Salix and its Affiliates hereunder and not for any other purposes whatsoever. 

(h) Glenmark shall have the right to use the Agreed Scale-Up Equipment or any Supplement Scale-Up Equipment for purposes other than to
supply Salix with such quantities of Compound as Glenmark is obligated to supply to Salix pursuant to the provisions of Section 2.1 and 2.2 hereof provided that Salix gives written consent, which shall not be unreasonably withheld, and such use
does not interfere with Glenmark’s ability to supply Salix with such quantities of Compound as Glenmark is obligated to supply to Salix pursuant to the provisions of Section 2.1 and 2.2 hereof. 

2.9 Costs and Expenses. Except as otherwise set forth in Sections 2.8(c) and 2.10(b), [*] shall be solely responsible for all
costs and expenses incurred in connection with the Manufacture of Compound hereunder, including costs and expenses of personnel, quality control testing, Manufacturing facilities and equipment, and Glenmark-Supplied Materials. 

2.10 Amendment of Specifications. 
 (a) In the event that an amendment to the Specifications, the Manufacturing process, or the test methods for the Compound is required in writing by any Regulatory Authority, Salix promptly shall provide
Glenmark with appropriate documentation relating to any such changes to the Specifications or Manufacturing process to the extent that such changes affect Glenmark’s Manufacturing of the Compound hereunder. So long as the process capability can
meet such amendment to Specifications or Manufacturing process required by the Regulatory Authority, Glenmark shall promptly implement such changes in accordance with the change control procedures applicable under GMP. In the event that the
process capability cannot meet such an amendment to Specifications or Manufacturing process required by the Regulatory Authority, then the Parties will pursue good faith discussions with respect to the identification and implementation of
arrangements that will permit Glenmark to meet such amendment. Salix may request any other amendment to the Specifications, the Manufacturing process, or the test methods for the Compound, in which event the Parties shall meet to discuss
such proposed amendment in good faith. Salix promptly shall provide Glenmark with appropriate documentation relating to any such changes to the Specifications or Manufacturing process to the extent that such changes affect Glenmark’s
Manufacturing of the Compound hereunder. Promptly thereafter, Glenmark 
 [*] Confidential treatment requested. 

  
 19 

 
shall use its commercially reasonable efforts to implement any such change agreed to by the Parties. Glenmark shall not, in any respect, amend, modify or supplement the Specifications, the
Manufacturing process, or the test methods for the Compound or any Materials or sources of Materials used in connection with Manufacturing the Compound without the prior written consent of Salix. 

(b) [*] shall reimburse [*] for reasonable expenses that are actually incurred by [*] in connection with any amendment of the
Specifications or the Manufacturing process for the Compound required by Salix, including reasonable costs of capital equipment and process upgrades and obsolescence of Materials, goods-in-process, and finished goods not suitable for other use in
the business or operations of Glenmark or any of its Affiliates; provided, however, that [*]’s liability for such reimbursement shall be limited to levels of inventory that are customary in pharmaceutical manufacturing operations.

 (c) [*] shall be solely responsible for any and all increased costs or expenses incurred by [*] or [*] as a result of any
amendment of the Specifications or the Manufacturing process for the Compound (i) requested by Glenmark and consented to by Salix or (ii) required by Salix as a result of Glenmark’s failure to Manufacture the Compound in conformity
with the Specifications. 
 2.11 Quality Agreement. Within [*] ([*]) days after the Amendment Effective Date, and in any
event, prior to any commercial sale of the Compound, Salix and Glenmark shall prepare and enter into a reasonable and customary quality assurance agreement, upon terms generally consistent with the existing quality agreement between Glenmark and
Napo with such modifications thereto as either Party may reasonably request (the “Quality Agreement”). Each Party shall duly and punctually perform all of its obligations under the Quality Agreement. 

2.12 Quality Control Analyses and Release. Glenmark shall be responsible for all quality control analyses of the Compound and all
Compound shall be released by Glenmark, in each case in accordance with the terms of the Quality Agreement. 
 2.13
Maintenance of Facilities and Compound Equipment. 
 (a) Except as otherwise approved in writing by Salix, Glenmark shall
Manufacture the Compound exclusively at the Facilities under GMP. 
 (b) Glenmark shall ensure that any and all licenses,
registrations, and Regulatory Authority approvals required by Applicable Law are and shall be obtained in connection with each Facility and equipment used in connection with the Manufacture of the Compound by Glenmark. 

[*] Confidential treatment requested. 

  
 20 

 (c) Glenmark shall maintain the Facilities and such equipment in a state of repair and
operating efficiency consistent with the requirements of the Specifications, the Regulatory Approvals, GMP and all other Applicable Law. 
 (d) Glenmark shall (i) install Compound Equipment only in the respective Facility as per Schedule 1.5 and shall not thereafter remove or permit the taking of the Compound Equipment from such
Facility without Salix’s prior written consent; (ii) make no alterations or additions to the Compound Equipment, other than those that are legally necessary or that will not impair the value or performance of the Compound Equipment and are
readily removable without damage to such equipment; (iii) use, maintain and operate the Compound Equipment exclusively for the purpose for which it was designed and so as to cause such equipment to be in good repair and operating condition and
in at least the same condition as when first obtained and installed by Glenmark, except for ordinary wear and tear; (iv) insure all Compound Equipment against casualty loss for the full replacement cost thereof; and, (v) in the event of
loss of any of the Compound Equipment from any cause whatsoever or any damage thereto, promptly replace or repair such Compound Equipment. 
 (e) Glenmark shall maintain in each Facility adequate and segregated holding accommodations for the Compound and the Materials used in Manufacturing the Compound in accordance with the Specifications, the
Regulatory Approvals, GMP and all other Applicable Law. 
 (f) Glenmark shall only use disposal services or sites that have
appropriate environmental permits and are in compliance with Applicable Law. 
 2.14 Regulatory Cooperation of Glenmark.
Glenmark shall cooperate with any reasonable requests for assistance from Salix with respect to obtaining and maintaining any and all Regulatory Approvals, including by: 
 (a) at [*] cost and expense, making its employees, consultants and other staff available upon reasonable notice during normal business hours to attend meetings with Regulatory Authorities concerning the
Compound and the Product; and 
 (b) at [*] cost and expense, disclosing and making available to Salix, in such form as may be
required by any applicable Regulatory Authority, all Manufacturing and quality control data, CMC Data and other information related to the Compound and the Manufacturing process therefor as is reasonably necessary to prepare, file, obtain and
maintain any Regulatory Approval. 
 2.15 Inspection by Salix. Glenmark agrees that Salix and its agents shall have the
right [*] each Calendar Year, upon reasonable prior notice to Glenmark and during normal business hours, to inspect those portions of each Facility where Manufacture of the Compound takes place, as well as the Manufacturing of the Compound,
including 
 [*] Confidential treatment requested. 

  
 21 

 
inspection of (a) the Materials used in the Manufacture of the Compound, (b) the holding facilities for such Materials, (c) the equipment used in the Manufacture of the Compound,
and (d) all records relating to such Manufacturing and the Facility (only to the extent they relate to the Compound). Following such audit, Salix shall discuss its observations and conclusions with Glenmark and Glenmark shall use its
commercially reasonable efforts to implement such corrective actions as may be requested reasonably and in good faith by Salix within [*] ([*]) days after notification thereof by Salix or such longer period as may be reasonable in the circumstances
as determined by Glenmark after consultation with Salix or agreed by the Parties. 
 2.16 Notification of Regulatory
Inspections; Communications. Glenmark shall notify Salix by telephone within [*] ([*]) hours, and in writing within [*] ([8]) business days, after learning of any proposed visit or inspection by any Regulatory Authority, the specific (but not
necessarily exclusive) focus of which is on those portions of a Facility where Manufacture of the Compound takes place or on operations of a Facility material to the Manufacture of the Compound, and shall use its commercially reasonable efforts
to permit Salix or its agents to be present and participate in such visit or inspection. For purposes of clarity, routine inspection of a Facility which may include inspection of those portions of the Facility where Manufacture of the Compound takes
place shall not trigger Glenmark’s notification obligation under this Section 2.16. 
 2.17 Recalls and
Withdrawals. [*] promptly shall [*] for all costs incurred by [*] in connection with recalls, market withdrawals, and returns and destruction of Product containing any non-conforming Compound (as determined pursuant to Section 2.7(d)) as
and to the extent and only to the extent any such recall, market withdrawal or return or destruction of Product is the direct result of [*]’s breach of its warranties under Section 2.6 or [*]’s gross negligence or willful misconduct.
[*] shall have the right to offset any such costs against any payments owed by [*] to [*] under this Agreement. All other costs for recalls, market withdrawals and returns and destruction of Product shall be the sole and exclusive responsibility of
[*] (including any recalls, market withdrawals and returns and destruction of Product as and to the extent attributable to the failure of [*] to conform to applicable Specifications as of the time of its delivery to [*] hereunder). 

2.18 Compliance with Applicable Laws. Glenmark shall comply, and shall cause each of its Material suppliers (other than Salix and
its Affiliates) to comply, with GMP and all other Applicable Law in carrying out the Manufacturing of the Compound and its other duties and obligations under this Agreement. 
 2.19 Retention of Manufacturing Records and Samples. 
 (a) Glenmark shall
generate, retain and maintain: 
 [*] Confidential treatment requested. 

  
 22 

 (i) all records necessary to comply with GMP and all other Applicable Law relating to the
Manufacture of the Compound. Without limiting the foregoing, records shall be made concurrently with the performance of each step in the Manufacture of the Compound and in such a manner that at any time successive steps in the Manufacture and
distribution of any batch may be traced by an inspector. Such records shall be legible and indelible, shall identify the person immediately responsible, shall include dates of the various steps and be as detailed as necessary for a clear
understanding of each step by an individual experienced in the manufacture of pharmaceutical products; 
 (ii) all Manufacturing
records, standard operating procedures, equipment log books, batch manufacturing records, laboratory notebooks and all raw data relating to the Manufacturing of the Compound; 
 (iii) samples of each batch and Materials. Samples shall include a quantity of representative material of each batch and Materials sufficient to perform at least full duplicate quality control testing,
and shall specify the dates of Manufacture and packaging thereof. Samples so retained shall be selected at random from either final container material or from bulk and final containers; provided that they include at least one final container
as a final package, or package-equivalent of such filling of each batch. Such sample shall be stored at temperatures and under conditions which will maintain the identity and integrity of the relevant sample; and 

(iv) such other records and samples that Glenmark maintains in the ordinary course of business, as Salix reasonably may require in order
to ensure compliance by Glenmark with the terms of this Agreement and Applicable Law. 
 (b) Without prejudice to
Glenmark’s obligations pursuant to Section 2.19(a), Glenmark shall diligently complete the master batch record for the Compound during the Manufacture of such Compound. 

(c) All materials, samples, records and other items referred to in Sections 2.19(a) and 2.19(b) shall be retained by
Glenmark for the longer of (i) such period as may be required by GMP and all other Applicable Law and (ii) [*] ([*]) years. 
 2.20 No Other Supply. Glenmark shall not, and Glenmark shall cause its Affiliates not to, Manufacture or supply the Compound to or for any Person other than (a) Salix and its Affiliates under
and pursuant to this Agreement, (b) [*] under and pursuant to the [*] Glenmark Agreement, and (c) [*] as permitted under the [*] Glenmark Agreement. 
 [*] Confidential treatment requested. 

  
 23 

 2.21 Shortages. In the event that the amount of Compound which Glenmark Manufactures
is less than the amount required to meet the requirements of all Persons permitted to be supplied by Glenmark pursuant to Section 2.20, the total supply Manufactured by Glenmark shall be apportioned as follows: 

(a) Compound up to the amount of the then-current Augmented Capacity (pro rated as necessary to reflect any period less
than a year) minus the Current Capacity (pro rated as necessary to reflect any period less than a year) shall first to be allocated to [*] to the extent necessary to satisfy the good faith anticipated volume requirements of Compound for the next [*]
([*]) months of [*]. 
 (b) Any Compound remaining after compliance with Section 2.21(a) shall be allocated,
first, to those Persons (including, for the avoidance of doubt, Salix if it or its Affiliates, licensees or sublicensees has a pending or approved Marketing Authorization) with pending or approved Marketing Authorizations, pro rata on the
basis of each such Person’s good faith anticipated volume requirements of the Compound for the next [*] ([*]) months for itself and its Affiliates, licensees and sublicensees in respect of those countries or jurisdictions where such Person (or
its Affiliates, licensees or sublicensees) has a pending or approved Marketing Authorization; second, to those Persons who paid for the Compound Equipment, pro rata on the basis of each such Person’s good faith anticipated volume
requirements of the Compound for the next [*] ([*]) months; and third, as agreed by the Parties in good faith. 
 2.22
Second Source. Notwithstanding anything to the contrary herein, but subject to Salix’s obligations under Section 2.1(b), Salix shall have the right, at its own expense, to secure a Third Party Manufacturer to Manufacture Compound
for supply to Salix; provided, however, that no such Third Party Manufacturer shall be located in any country that is included in the Glenmark Territory. Glenmark shall use its commercially reasonable efforts to assist Salix to qualify such
Third Party Manufacturer designated by Salix to Manufacture such Compound, and provide to such Third Party Manufacturer such technical assistance, as Salix may reasonably request and such Third Party Manufacturer may reasonably require in order to
Manufacture the Compound at Salix’s sole cost and expense, provided that the technical assistance is for no more than [*] (equal to [*] work hours each). [*] shall also promptly grant to such Third Party Manufacturer a Third Party
Manufacturer License, provided that Salix shall compensate [*] in the manner set forth in Schedule 2.5(b), subject to all of the limitations set forth in such Schedule including the limitation with respect to the [*] ([*]) year
duration of such obligations and Schedule 1.37, Section III. 
 ARTICLE III. GLOBAL COORDINATION 

3.1 Global Cooperation and Coordination. Each of the Parties holds certain 

[*] Confidential treatment requested. 

  
 24 

 
licenses from Napo permitting it to Exploit the Product in certain fields of use in certain territories. Accordingly, each of the Parties has an interest in enhancing the development and
commercialization of the Product in those fields and territories to which its licenses extend. Each Party hereby acknowledges that the maximum commercial potential of the Product in its field of use and territories will be achieved through the
coordinated global development and commercialization. To that end, each of the Parties hereby agrees to cooperate and coordinate with the other Party to support the global development, approval by Regulatory Authorities, commercialization and other
Exploitation of the Product. Notwithstanding the foregoing, however, the Parties acknowledge and agree that the provisions of this Article III are without prejudice to the provisions of Section 9.13 and all of their activities contemplated by
this Article III shall be conducted by each Party in its individual capacity and as an independent party. Nothing in this Article III shall constitute or give rise to a partnership, agency, employer, employee or joint venture relationship between
the Parties. 
 3.2 Consultation. The Parties shall consult with each other on a regular basis, either in writing, by
telephone, or through face-to-face meetings, as the Parties may deem most expedient, with regard to all aspects of the development and commercialization of the Product. Without limiting the foregoing, each Party shall designate by written notice to
the other Party a single senior executive of such Party to serve as the principal contact with such other Party for purposes of the cooperation and coordination contemplated by this Article 3. Each Party shall ensure that at all times during the
Term it has designated such a senior executive for such purpose. 
 3.3 Regulatory Matters. 

(a) Rights of Reference. Each Party hereby grants to the other Party rights of reference in and to all Regulatory
Documentation filed by such Party with any Regulatory Authority. The Parties shall negotiate in good faith and implement appropriate provisions, consistent with Applicable Law, in respect of mutual adverse event reporting and mutual access to, and
mutual exchange between the Parties of, information necessary for each Party to adhere to regulatory requirements. Without limiting the foregoing, each Party shall have the right to cross reference, file or incorporate by reference any regulatory
submission or Drug Master File (and any data contained therein) for the Product, or any component thereof (including any Regulatory Approvals), in order to support regulatory submissions that such Party has the right to make. 

(b) Regulatory Inspections. If any governmental or Regulatory Authority takes, or gives notice of its intent to
take, any other regulatory action alleging improper or inadequate Manufacturing practices (including the issuance of a “Notice of Inspectional Observations,” “Warning Letter” or the equivalent) with respect to those portions of
the Facility where Manufacture of the Compound takes place, such Party shall notify the other Party by telephone within twenty-four (24) hours, and in writing within one (1) business day of such contact or notice, or sooner if necessary to
permit such other Party to be present at, or otherwise participate in, any such inspection or regulatory action with respect to the Compound and shall supply such other Party with 

  
 25 

 all information pertinent thereto. Such other Party shall have the right to be present at
and to participate in any such inspection or regulatory action with respect to the Compound. The inspected Party shall provide the other Party with copies of all documentation issued or inspected by any governmental or Regulatory Authority in
connection with such inspection or regulatory action and any response thereto proposed by the inspected Party. No such responses shall contain any false or misleading information, or omit any information necessary to make such response not false or
misleading, with respect to the Compound. 
 (c) Access to Data. Each Party shall provide the other Party
on a timely basis with access to all material pre-clinical data and clinical data compiled in support of a an application for Regulatory Approval or other regulatory filings with respect to the Product, when and as such pre-clinical data or clinical
data become available. Each Party shall provide the other Party with Regulatory Documentation within a reasonable timeframe of receipt or production thereof and, to the extent applicable, within the timeframe as is necessary for the responsible
Party to take action or comply with any requirement of any Regulatory Authority applicable to the responsible Party. 
 (d) Communications with Regulatory Authorities. As between Salix and Glenmark, Salix shall have sole responsibility and authority to communicate with Regulatory Authorities with respect to the Drug
Master File for the Compound; provided that, from and after the date that such Drug Master File is transferred to Glenmark, then Glenmark shall have the sole responsibility and authority to communicate with Regulatory Authorities with respect
to such Drug Master File. Subject to the foregoing, (i) Glenmark shall have the sole responsibility and authority to communicate with Regulatory Authorities during the term of the Napo-Glenmark Agreement in relation to the Product in the
Glenmark Territory and for the fields of use exclusively granted Glenmark in the Glenmark Territory and (ii) in relation to the Product outside the Glenmark Territory and outside the fields of use exclusively granted to Glenmark in the Glenmark
Territory, either Napo or Salix shall have sole responsibility and authority to communicate with Regulatory Authorities with respect to such Product. 
 (e) Conduct of Recalls. As between Salix and Glenmark, Salix shall have the sole responsibility and authority to conduct, and shall have the final decision whether to implement, all voluntary and
involuntary recalls, stop sales, field corrections or other related actions (collectively, “Recalls”) of the Product in and with respect to all fields of use in all countries worldwide, except for those countries included in the
General Territory (as defined in the Napo-Glenmark Agreement), but only in the field of use relating to HIV/AIDS-related diarrhea and pediatric diarrhea, and those countries included in the AAID Specific Territory (as defined in the Napo-Glenmark
Agreement), but only in the field of use relating to adult acute infectious diarrhea, with respect to which fields of use in the specified countries Glenmark shall have sole responsibility and authority to conduct or implement Recalls during the
term of the Napo-Glenmark Agreement. Glenmark and Salix shall cooperate and each shall 

  
 26 

 provide such assistance to the other in respect of Recalls of the Product as the other may
reasonably request. 
 3.4 Trademarks. The Parties shall cooperate in all respects for the purpose of achieving
appropriate coordination and harmonization of the use and manner of use of trademarks, trade dress, and trade names in respect of the Product on a global basis. 
 ARTICLE IV. INTELLECTUAL PROPERTY 
 4.1 Ownership. 

(a) Salix shall own all right, title and interest in and to (i) the Specifications and the Salix Information and
(ii) any and all Compound Inventions. Salix hereby grants to Glenmark and its Affiliates the right to use the Compound Inventions on the same terms and conditions set forth in Section 2.1 of the Napo-Glenmark Agreement, as such agreement
is in effect as of the Amendment Effective Date. Glenmark shall, and shall cause its Affiliates to, promptly disclose in writing to Salix the discovery, development, making, conception or reduction to practice of any Compound Invention and shall and
does hereby, and shall cause its Affiliates to, assign to Salix any and all right, title or interest Glenmark or its Affiliates may have in or to any Compound Invention. Glenmark shall execute any documents and perform such other acts as may be
reasonably requested by Salix in order to secure, perfect, confirm, exercise or enforce Salix’s foregoing rights. 
 (b) Glenmark shall own all right, title and interest in and to any manufacturing technique or process that is not derived from or based on the Specifications, any Salix Information or any Compound
Invention that is conceived, discovered, developed or otherwise made, solely by or on behalf of Glenmark as a result of Glenmark’s performance of its obligations hereunder (the “Glenmark Inventions”). Glenmark shall, and shall
cause its Affiliates to, promptly disclose in writing to Salix the discovery, development, making, conception or reduction to practice of any Glenmark Invention. Subject to Schedule 1.37, Section III, Glenmark shall, and does hereby, grant to Salix
a non-exclusive license to Glenmark Inventions and Glenmark Invention Patents to Exploit the Compound and Products in all fields of use in all countries worldwide, except for (i) those countries included in the General Territory (as such term
is defined in the Napo-Glenmark Agreement as such agreement is in effect as of the Amendment Effective Date), but only in the field of use relating to HIV/AIDS-related diarrhea and pediatric diarrhea, and (ii) those countries included in the
AAID Specific Territory (as such term is defined in the Napo-Glenmark Agreement as such agreement is in effect as of the Amendment Effective Date), but only in the field of use relating to adult acute infectious diarrhea. 

(c) Glenmark and Salix shall jointly own all right, title and interest in and to any and all Joint Inventions. Each of
Glenmark and Salix shall, and shall cause its respective Affiliates to, promptly disclose in writing to the other Party the discovery, development, making, conception or reduction to practice of any Joint Invention. For those countries in the
Territory where a specific license is required to be 

  
 27 

 granted by a Joint Invention owner to the other Joint Invention owner in order for the other
Joint Invention owner to practice such Joint Inventions in such countries in the Territory, Glenmark shall, and does hereby, grant to Salix a non-exclusive fully paid up license to Glenmark’s interest in all Joint Inventions to Exploit the
Compound and Products in all fields of use in all countries worldwide, except for (i) those countries included in the General Territory, but only in the field of use relating to HIV/AIDS-related diarrhea and pediatric diarrhea, and
(ii) those countries included in the AAID Specific Territory, but only in the field of use relating to adult acute infectious diarrhea. For those countries in the Territory where a specific license is required to be granted by a Joint Invention
owner to the other Joint Invention owner in order for the other Joint Invention owner to practice such Joint Inventions in such countries in the Territory, Salix shall, and does hereby, grant to Glenmark a non-exclusive fully paid-up license to
Salix’s interest in all Joint Inventions to Exploit the Compound and Products in (i) those countries included in the General Territory, but only in the field of use relating to HIV/AIDS-related diarrhea and pediatric diarrhea, and
(ii) those countries included in the AAID Specific Territory, but only in the field of use relating to adult acute infectious diarrhea. 
 (d) Without limiting the provisions of Article VI, Glenmark shall use the Specifications and Salix Information solely for purposes of performing its supply obligations hereunder. 

4.2 Patent Maintenance and Prosecution. 
 (a) Compound Invention Patents. 
 (i) [*] shall have sole discretion and
responsibility to prepare, file, prosecute and maintain all patent applications and patents covering Compound Inventions (collectively, the “Compound Invention Patents”, and each, a “Compound Invention Patent”) and
shall be responsible for related interference and opposition proceedings; provided, however, that if [*] plans to abandon any Compound Invention Patent, [*] shall notify [*] in writing at least [*] ([*]) days in advance of the due date
of any payment or other administrative action that is required to maintain such Compound Invention Patent (i.e., an administrative action that involves routine and customary filings, it being understood that interference, opposition, reissue
and re-examination proceedings, prosecution or defense of infringement actions, and the like, shall not be considered administrative actions), and [*] may elect, upon written notice within such [*] ([*])-day period to [*], to make such payment or
take such administrative action, on behalf of [*]. Except as expressly permitted in this Section 4.2(a)(i), [*] shall have no right to prepare, file, prosecute or maintain any Compound Invention Patents. 

(ii) Costs and expenses of filing, prosecuting and maintaining (including any costs and expenses of patent interference, opposition,
reissue and 
 [*] Confidential treatment requested. 

  
 28 

 
re-examination proceedings) Compound Invention Patents as contemplated by Section 4.2(a)(i) shall be borne by [*] such filing, prosecution and maintenance. 

(b) Glenmark Invention Patents. 
 (i) [*] shall have the first right, but not the obligation, to prepare, file, prosecute and maintain all patent applications and patents covering Glenmark Inventions (collectively, the “Glenmark
Invention Patents”, and each, a “Glenmark Invention Patent”) and shall be responsible for related interference and opposition proceedings; provided, however, that if [*] plans to abandon any Glenmark Invention
Patent, [*] shall notify [*] in writing at least [*] ([*]) days in advance of the due date of any payment or other administrative action that is required to maintain such Glenmark Invention Patent (i.e., an administrative action that involves
routine and customary filings, it being understood that interference, opposition, reissue and re-examination proceedings, prosecution or defense of infringement actions, and the like, shall not be considered administrative actions), and [*] may
elect, upon written notice within such [*] ([*])-day period to [*], to make such payment or take such administrative action, on behalf of [*]. Except as expressly permitted in this Section 4.2(b)(i), [*] shall have no right to prepare, file,
prosecute or maintain any Glenmark Invention Patents. 
 (ii) If [*] does not wish to file, prosecute or maintain any Glenmark
Invention Patent or maintain or defend such Glenmark Invention Patent in a particular country, it shall notify [*] in writing and, if [*] elects to maintain such Glenmark Invention Patent as contemplated by Section 4.2(b)(i), [*] shall, and
shall cause its Affiliates, as applicable, to (A) reasonably cooperate with [*] in this regard and, (B) upon [*]’s request, promptly release or assign to [*], without compensation, all right, title and interest in and to such
invention in such country. In the event of such assignment, [*] hereby grants to [*] a [*], [*] license under the relevant Glenmark Invention Patent to use for any purpose in the Territory. 

(iii) Costs and expenses of filing, prosecuting and maintaining (including any costs and expenses of patent interference, opposition,
reissue and re-examination proceedings) Glenmark Invention Patents as contemplated by Section 4.2(b)(i) and (ii) shall be borne by [*] such filing, prosecution and maintenance. 

(c) Joint Invention Patents. 
 (i) Salix and Glenmark shall collaborate to determine which Party shall be responsible for preparing, filing, prosecuting and maintaining all patent applications and patents covering Joint Inventions
(collectively, the “Joint Invention 
 [*] Confidential treatment requested. 

  
 29 

 
Patents”, and each, a “Joint Invention Patent”) and for related interference and opposition proceedings on behalf of both Parties based on a good faith determination
of the relative contributions of the Parties to the invention(s) claimed or covered by such Joint Invention Patent and the relative level of interest of the Parties in such invention(s). At least [*] ([*]) business days prior to the contemplated
filing with respect to a Joint Invention Patent, the [*] for such activities for such Joint Invention Patent shall submit a substantially completed draft of such Joint Invention Patent to the other Party for its review and approval, and shall
incorporate any reasonable comments provided by the other Party. If the [*] does not wish to file, prosecute or maintain any Joint Invention Patent or maintain or defend such Joint Invention Patent in a particular country, it shall notify the other
Party in writing and, if the other Party elects to maintain such Joint Invention Patent, such first Party shall, and shall cause its Affiliates, as applicable, to (A) reasonably cooperate with such first Party in this regard and (B) upon
such first Party’s request, promptly release or assign to such first Party, without compensation, all right, title and interest in and to such invention in such country (whereupon such Joint Invention Patent shall cease to be a Joint Invention
Patent and thereafter shall be deemed to be a [*] or a Compound Invention Patent, as applicable, for purposes of this Article IV). 
 (ii) Costs and expenses of filing, prosecuting and maintaining (including costs and expenses of patent interference, opposition, reissue and re-examination proceedings) Joint Invention Patents as
contemplated by Section 4.2(c)(i) shall be shall be borne by [*] such filing, prosecution and maintenance. 

(d) Each Party shall assist and cooperate with the other Party as such other Party may reasonably request from time to
time in connection with its activities set forth in Sections 4.2(a), 4.2(b) and 4.2(c). Each Party shall keep the other Party currently informed of all steps to be taken in the preparation and prosecution of all applications filed by it according to
this Section 4.2 and shall furnish such other Party with copies of such applications for Patents, amendments thereto and other related correspondence to and from patent offices, and, to the extent reasonably practicable, permit such other Party
an opportunity to offer its comments thereon before making a submission to a patent office which could materially affect the scope or validity of the patent coverage that may result. Such other Party shall offer its comments, if any, promptly.

 (e) With respect to Patents filed in any country other than those countries included in the Glenmark
Territory, [*] shall be responsible for making decisions regarding patent term extensions, including supplementary protection certificates and any other extensions that are now or become available in the future, wherever applicable, for such
Patents. With respect to Patents filed in any country included in the Glenmark Territory, the [*] regarding patent term extensions, including supplementary protection certificates and 
 [*] Confidential treatment requested. 

  
 30 

 any other extensions that are now or become available in the future, wherever applicable,
for such Patents. Notwithstanding the foregoing, the Parties shall coordinate their activities with respect to any patent term extension with respect to all Patents in order to secure the optimal protection for the Product available under Applicable
Law. 
 4.3 Enforcement of Patents. 

(a) If any Patent is allegedly or actually infringed by any Person in a manner relating to the Product, the Party first
having knowledge of such infringement shall promptly notify the other in writing. The notice shall set forth the facts of that infringement in reasonable detail. 

(b) As between the Parties, [*] shall have the first right, but not the obligation, to control the prosecution of any
infringement described in this Section 4.3(a). [*] shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. If [*] does not initiate an infringement action within [*] ([*]) days (or [*] ([*])
days in the case of an action brought under the Hatch-Waxman Act or within the timeframe of any other relevant regulatory or statutory framework that may govern) of learning of the infringement, [*] shall have the right, but not the obligation, to
bring such an action solely (i) with respect to any [*] or [*] in any country included in the Glenmark Territory and, (ii) subject to the prior written consent of [*], with respect to any [*] or [*] in countries outside the [*];
provided that, if the Patent at issue is the only patent protecting the Product, [*] shall in any event consult with [*] with respect to any such action and shall obtain [*] written consent prior to taking any steps in respect of such action.
[*] shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

(c) In the event that a Party entitled to bring an infringement action does so in accordance with this
Section 4.3(a), the other Party shall cooperate fully, including furnishing of a power of attorney, being joined as a party plaintiff or indispensable party in such action, providing access to relevant documents and other evidence, and making
its employees available at reasonable business hours. If a Party pursues an action against such alleged infringement, it shall consider in good faith any comments from the other Party and shall keep the other Party reasonably informed of any steps
taken to preclude such infringement. 
 (d) Any costs and expenses relating to any enforcement action commenced
pursuant to this Section 4.3 by [*] shall be borne by [*]. Any costs and expenses relating to any enforcement action commenced pursuant to this Section 4.3 by [*] shall be borne by [*]. Any damages or other amounts collected shall be first
allocated to reimburse the Parties for their costs and expenses in 
 [*] Confidential treatment requested. 

  
 31 

 making such recovery (which amounts shall be allocated pro rata if insufficient to cover the
totality of such expenses). Any remainder after such reimbursement is made shall be retained by [*]; provided, however, that to the extent that any award or settlement (whether by judgment or otherwise) is attributable to loss of sales
or profits with respect to the Product, the Parties shall negotiate in good faith an appropriate allocation of such remainder to reflect the economic interests of the Parties under this Agreement with respect to the Product. 

4.4 Third Person Litigation. 
 (a) If any Person institutes against Glenmark any action that alleges that the Manufacture of Compound hereunder in accordance with the terms hereof infringes the intellectual property rights held by such
Person, then, as between Glenmark and Salix, [*] shall have the first right, but not the obligation, to contest, and assume direction and control of the defense of, such action, including the right to settle such action; provided that, prior
to any such settlement, [*] provides its written consent (such consent not to be unreasonably withheld, conditioned or delayed). If [*] determines not to defend against such action, [*] shall, at its sole cost and expense, have the right but not the
obligation to control the defense of such action solely (i) with respect to any [*] or [*] in any country included in the [*] and, (ii) subject to the prior written consent of [*], with respect to any [*] or [*] in countries outside the
[*]; provided that, if the Patent at issue is the only patent protecting the Product, [*] shall in any event consult with [*] with respect to any such action and shall obtain [*]’s written consent prior to taking any steps in respect of
such action. [*] shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. 
 (b) Any costs and expenses relating to any enforcement action commenced pursuant to this Section 4.4 shall be borne by [*]. Any damages or other amounts collected shall be first allocated to
reimburse the Parties for their costs and expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses). Any remainder after such reimbursement is made shall be retained by [*].

 (c) In the event that a Party entitled to defend an infringement action does so in accordance with this
Section 4.4, the other Party shall cooperate fully, including providing access to relevant documents and other evidence and making its employees available at reasonable business hours. If a Party pursues the defense of 

[*] Confidential treatment requested. 

  
 32 

 such an infringement action, it shall consider in good faith any comments from the other Party and shall
keep the other Party reasonably informed of any steps taken to preclude such infringement. 
 4.5 Third Party Licenses.
If, in the absence of a license from a Person, the Manufacture of the Compound hereunder in accordance with the terms hereof infringes or misappropriates any patent or any intellectual property right of such Person, such that Glenmark or any of its
Affiliates cannot Manufacture such Compound without infringing the patent or intellectual property rights of such Person, then [*] shall have the first right to take the lead on negotiating the terms of each such license; provided that if [*]
does not take such lead, then [*] may do so; provided further that the negotiating Party shall obtain the written consent of the other Party prior to entering into any such license, such consent not to be unreasonably withheld, conditioned,
or delayed. The Parties shall negotiate in good faith an appropriate allocation of any royalties or other payments to be made pursuant to any such license so as to reflect the economic interests of the Parties under this Agreement with respect to
the Product. 
 ARTICLE V. REPRESENTATIONS AND WARRANTIES; COVENANTS 

5.1 Representations and Warranties of Each Party. Each Party hereby represents and warrants to the other Party as of the Amendment
Effective Date as follows: 
 (a) Such Party (i) is duly formed and in good standing under the laws of the jurisdiction of
its formation, (ii) has the power and authority and the legal right to enter into this Agreement and perform its obligations hereunder, and (iii) has taken all necessary action on its part required to authorize the execution and delivery
of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation of such Party and is enforceable against it in
accordance with its terms, subject to the effects of bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and
general principles of equity, whether enforceability is considered a proceeding at law or equity. 
 (b) All necessary consents,
approvals and authorizations of all regulatory and governmental authorities and other Persons required to be obtained by such Party in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have
been obtained. 
 (c) The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder
(i) do not and will not conflict with or violate any requirement of applicable law or any provision of the articles of incorporation, bylaws, limited partnership agreement or other similar documents of such Party and (ii) do not

 [*] Confidential treatment requested. 

  
 33 

 and will not conflict with, violate, or breach, or constitute a default or require any
consent under, any contractual obligation or court or administrative order by which such Party is bound. 
 5.2 Additional
Warranties and Covenants of Glenmark. Glenmark hereby represents, warrants and covenants to Salix that (a) neither Glenmark nor any of its Affiliates has been debarred or is subject to debarment pursuant to Section 306 of the FFDCA or
any similar law in any country in the Specified Territory or listed on either Excluded List or any similar list in any country in the Specified Territory and (b) neither Glenmark nor any of its Affiliates will use in any capacity, in connection
with the services to be performed under this Agreement, any Person who has been debarred pursuant to Section 306 of the FFDCA or any similar law in any country in the Specified Territory, or who is the subject of a conviction described in such
section, or listed on either Excluded List; provided that, in each case ((a) and (b)), with respect to any such similar laws or lists in any country in the Specified Territory other than the United States, Salix has identified for Glenmark
with specificity such law or list. Glenmark shall inform Salix in writing immediately if it or, to its knowledge, any Person who is performing services hereunder is debarred or is the subject of a conviction described in Section 306 of the
FFDCA or any similar law in any country in the Specified Territory or listed on either Excluded List, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or is threatened, relating to the debarment or
conviction under Section 306 of the FFDCA or any similar law in any country in the Specified Territory, or listing on either Excluded List, of Glenmark or, to Glenmark’s knowledge, any other Person performing services hereunder;
provided that, with respect to any such similar laws or lists in any country in the Specified Territory other than the United States, Salix has identified for Glenmark with specificity such law or list. 

5.3 Disclaimer of Other Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THE PARTIES MAKE NO REPRESENTATIONS AND
EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR WARRANTY OF MERCHANTABILITY. 
 ARTICLE VI. CONFIDENTIALITY 
 6.1 Confidential Information. Subject
to the provisions of Sections 6.2 and 6.3, at all times during the Term and for [*] ([*]) years following the expiration or termination of this Agreement, the Receiving Party (a) shall keep completely confidential and shall not publish or
otherwise disclose any Confidential Information furnished to it by the Disclosing Party, except to those of the Receiving Party’s employees, Affiliates, or consultants who have a need to know such information to perform such Party’s
obligations hereunder (and who shall be advised of the Receiving Party’s obligations hereunder and who are bound by confidentiality obligations with respect to such Confidential Information no less onerous than those set forth in this
Agreement) 
 [*] Confidential treatment requested. 

  
 34 

 
(collectively, “Recipients”) and (b) shall not use Confidential Information of the Disclosing Party directly or indirectly for any purpose other than performing its
obligations or exercising its rights hereunder. The Receiving Party shall be jointly and severally liable for any breach by any of its Recipients of the restrictions set forth in this Agreement. 

6.2 Exceptions to Confidentiality. The Receiving Party’s obligations set forth in this Agreement shall not extend to any
Confidential Information of the Disclosing Party: 
 (a) that is or hereafter becomes part of the public domain by public use,
publication, general knowledge or the like through no wrongful act, fault or negligence on the part of a Receiving Party or its Recipients; 
 (b) that is received from a third party without restriction and without breach of any agreement between such third party and the Disclosing Party; 

(c) that the Receiving Party can demonstrate by competent evidence was already in its possession without any limitation on use or
disclosure prior to its receipt from the Disclosing Party; provided, however, that this exception shall not apply with respect to any information or materials regarding the Compound that are provided to Glenmark by Salix under this
Agreement; 
 (d) that is generally made available to third parties by the Disclosing Party without restriction on disclosure; or

 (e) that the Receiving Party can demonstrate by competent evidence was independently developed by the Receiving Party.

 6.3 Disclosure. 
 (a) Each Party may disclose Confidential Information to the extent that such disclosure is: 
 (i) made in response to a valid order of a court of competent jurisdiction or other governmental body of a country or any political subdivision thereof of competent jurisdiction; provided,
however, that the Receiving Party shall first have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity to quash such order or to obtain a protective order requiring that the Confidential Information or
documents that are the subject of such order be held in confidence by such court or governmental body or, if disclosed, be used only for the purposes for which the order was issued; and provided further that if a disclosure order is not
quashed or a protective order is not obtained, the Confidential Information disclosed in response to such court or governmental order shall be limited to that information that is legally required to be disclosed in such response to such court or
governmental order; or 

  
 35 

 (ii) otherwise required by law or regulation, in the opinion of counsel to the Receiving
Party. 
 (b) Salix may disclose Confidential Information to the extent that such disclosure is made to Regulatory Authorities as
required in connection with any filing, application or request for Regulatory Approval; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information. 

6.4 Notification. The Receiving Party shall notify the Disclosing Party immediately, and cooperate with the Disclosing Party as
the Disclosing Party may reasonably request, upon the Receiving Party’s discovery of any loss or compromise of the Disclosing Party’s Confidential Information. 
 6.5 Remedies. Each Party agrees that the unauthorized use or disclosure of any information by the Receiving Party in violation of this Agreement will cause severe and irreparable damage to the
Disclosing Party. In the event of any violation of this Article V, the Receiving Party agrees that the Disclosing Party shall be authorized and entitled to obtain from any court of competent jurisdiction injunctive relief, whether preliminary or
permanent, without the necessity of proving irreparable harm or monetary damages, as well as any other relief permitted by Applicable Law. The Receiving Party agrees to waive any requirement that the Disclosing Party post bond as a condition for
obtaining any such relief. 
 6.6 Use of Names. Neither Party shall mention or otherwise use the name, insignia, symbol,
trademark, trade name or logotype of the other Party (or any abbreviation or adaptation thereof) in any publication, press release, promotional material or other form of publicity without the prior written approval of such other Party in each
instance. The restrictions imposed by this Section 6.6 shall not prohibit either Party from making any disclosure identifying the other Party that is required by applicable law; provided, however, that reasonable measures shall be
taken to assure confidential treatment of such information. 
 6.7 Press Releases. Except as expressly provided in
Section 6.3, neither Party shall make a press release or other public announcement regarding this Agreement, the terms hereof or the transactions contemplated hereby without the prior written approval of the other Party. Each Party shall
provide the other with the proposed text of any such press release or public announcement for review and approval, which approval shall not be unreasonably withheld, conditioned or delayed, as early as possible, but in no event less than four
(4) business days in advance of the publication, communication or dissemination thereof; provided, however, that the receiving Party shall be deemed to have approved any such press release or public announcement if it fails to
notify the proposing Party in writing of any objections to such press release or public announcement within three (3) business days after receipt by the receiving Party of the text of such public announcement. 

ARTICLE VII. TERM AND TERMINATION 
 7.1 Term. This Agreement shall commence as of the Amendment Effective Date and, unless earlier terminated in accordance with the terms hereof, shall expire on the tenth (10th) anniversary of
the Amendment Effective Date, unless extended for additional two (2) year periods, at Salix’s option, upon written notice given by Salix to Glenmark not less than six (6) months prior to the expiration of the then-current term (the
“Term”). 

  
 36 

 7.2 Termination. In addition to any other provision of this Agreement expressly
providing for termination of this Agreement, this Agreement may be terminated as follows: 
 (a) Salix may terminate this
Agreement immediately upon notice to Glenmark in the event that Regulatory Authorities cause the withdrawal of any Product from the US market for any reason or from any national market in the Territory for safety reasons. 

(b) Upon the termination of the Napo-Glenmark Agreement, Glenmark may terminate this Agreement upon eighteen (18) months’ prior
written notice to Salix; provided, however, that any such termination shall not become effective prior to the fifth anniversary of the Amendment Effective Date. 
 (c) This Agreement may be terminated by either Party: 
 (i) immediately upon
written notice if the other Party shall (a) file in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction a petition in bankruptcy or insolvency or for reorganization or for arrangement or for the
appointment of a receiver or trustee of that Party or of its assets, (b) propose a written agreement of composition or extension of its debts, (c) be served with an involuntary petition against it, filed in any insolvency proceeding, and
such petition shall not be dismissed within sixty (60) days after the filing thereof, (d) propose or be a party to any dissolution or liquidation, (e) make makes an assignment for the benefit of its creditors, or (f) admit in
writing its inability generally to pay its debts as they fall due in the general course; 
 (ii) immediately upon written notice
in the event of any material breach by the other Party in the performance of any of its obligations herein contained that has not been cured by the defaulting Party within thirty (30) days after receiving written notice thereof from the
non-breaching Party; provided, however, that any such termination by Glenmark shall not become effective prior to the fifth anniversary of the Amendment Effective Date; 
 (iii) upon at least thirty (30) days’ prior written notice to the other Party in the event that any Person sells, offers for sale, or distributes an unauthorized generic version of the Compound
or any Product in any national market in the Territory (such event, an “Other Product Entry”), which notice of termination, if given, must be given within thirty (30) days after the Other Product Entry; provided,
however, that any such termination by Glenmark shall not become effective prior to the fifth anniversary of the Amendment Effective Date; or 
 (iv) immediately upon written notice in the event that, as a result of an order of government or any other official authority, the continued operation of this Agreement in its entirety or in substantial
part is prevented or delayed for an unspecified and indeterminate period. 

  
 37 

 7.3 Effect of Expiration or Termination. 

(a) The expiration or earlier termination of this Agreement shall be without prejudice to any rights or obligations of the Parties that
may have accrued prior to such termination, and the provisions of Sections 4.1, 4.2, 4.3 and 4.4, Article VI, Sections 8.1, 8.2, 8.3 and 8.5 and Article IX, and this Section 7.3 shall survive the expiration or termination of this Agreement.
Except as otherwise expressly provided herein, termination of this Agreement in accordance with the provisions hereof shall not limit remedies that may otherwise be available at law or in equity. 

(b) Upon expiration or earlier termination of this Agreement, each Party, at the request of the other, shall return all data, files,
records and other materials in its possession or control containing or comprising the other Party’s Confidential Information except that the legal department of such Party may retain one copy for archival purposes. 

(c) Upon expiration or earlier termination of this Agreement, other than pursuant to Section 7.2(c)(i), at Salix’s option and
sole cost and expense, Glenmark shall use its commercially reasonable efforts promptly to assist Salix to qualify such Third Party Manufacturer designated by Salix to Manufacture such Compound, and provide, to such Third Party Manufacturer such
technical assistance, as Salix may reasonably request and such Third Party Manufacturer may reasonably require in order to Manufacture the Compound provided that the technical assistance is for no more than [*] (equal to [*] work hours each).
[*] shall also promptly grant to such Third Party Manufacturer a Third Party Manufacturer License, provided that Salix shall compensate [*] in the manner set forth in Schedule 2.5(b), subject to all of the limitations set forth in such
Schedule including the limitation with respect to the [*] ([*]) year duration of such obligations and Schedule 1.37, Section III. 
 (d) Subject to Section 7.3(e), upon termination of this Agreement for any reason, (i) Glenmark immediately shall cease all Manufacturing of the Compound pursuant to this Agreement, (ii) all
submitted but unfilled Purchase Orders automatically shall be cancelled, and (iii) Glenmark promptly shall return any remaining Salix-Supplied Material to Salix or its designee against Salix’s repayment to Glenmark of the amount paid by
Glenmark to Salix therefor. 
 (e) Subject to Glenmark’s continuing right to make Compound and use the Napo-Provided
Equipment, in the event of termination of this Agreement by Glenmark pursuant to 7.2(b), Glenmark shall continue to supply Compound to Salix pursuant to the terms of this Agreement for [*] ([*]) [*] following the date of notice of termination;
provided that, notwithstanding Section 2.2, Salix shall have the 
 [*] Confidential treatment requested. 

  
 38 

 
right to submit a revised Forecast promptly after the date Salix receives notice of such termination from Glenmark; provided further that Salix may elect, upon [*] ([*]) [*] prior written notice
to Glenmark, to extend such period for [*] periods, and shall have the right, notwithstanding Section 2.2, to submit a revised Forecast together with such notice. Thereafter, upon the mutual written agreement of the Parties, such period may be
extended for an additional [*] ([*]) [*]. In addition, if there is no Third Party Manufacturer that has been approved by the FDA and is referenced in Salix’s Regulatory Documentation in respect of the Product that is supplying Compound to Salix
as of the date of notice of such termination, then (i) Salix shall use commercially reasonable efforts to qualify a Third Party Manufacturer and (ii) Glenmark shall use commercially reasonable efforts to assist Salix in qualifying a Third
Party Manufacturer in accordance with Section 2.22, in each case ((i) and (ii)), within [*] ([*]) [*] of the date of notice of such termination. 
 (f) For purposes of clarification, termination of this Agreement does not preclude Glenmark from manufacturing Compound for its own use and the use of its Affiliates. 

ARTICLE VIII. INDEMNIFICATION 
 8.1 Glenmark Indemnification. Glenmark shall indemnify Salix, its Affiliates and its and their respective directors, officers, employees and agents (the “Salix Indemnified
Parties”), and defend and hold each of them harmless, from and against any and all Third Party claims, lawsuits, losses, damages, liabilities, penalties, costs and expenses (including reasonable attorneys’ fees and disbursements)
(collectively, “Losses”) incurred by any of them in connection with, arising from or occurring as a result of Glenmark’s gross negligence or willful misconduct in the performance of this Agreement, except, in each case,
for those Losses for which Salix has an obligation to indemnify the Glenmark Indemnified Parties pursuant to Section 8.2, as to which Losses each Party shall indemnify the other Party to the extent of its respective liability for such Losses.

 8.2 Salix Indemnification. Salix shall indemnify Glenmark, its Affiliates and its and their respective directors,
officers, employees and agents (the “Glenmark Indemnified Parties”), and defend and save each of them harmless, from and against any and all Losses incurred by any of them in connection with, arising from or occurring as a result of
(a) any Third Party Claim made by any Person that the Manufacture and supply of the Compound in accordance with the terms hereof infringes, misappropriates or otherwise violates the patent, trademark or other intellectual property rights of
such Person, (b) any Third Party Claim made by any Person relating to or arising out of death, personal injury, or other product liability, related to the marketing, sale, distribution or use of the Compound or the Product, and (c) the
gross negligence or willful misconduct of Salix or its subcontractors or agents, except, in each case, for those Losses for which 
 [*]
Confidential treatment requested. 

  
 39 

 
Glenmark has an obligation to indemnify the Salix Indemnified Parties pursuant to Section 8.1, as to which Losses each Party shall indemnify the other Party to the extent of its respective
liability for such Losses. 
 8.3 Indemnification Procedure. 

(a) Notice of Claim. The indemnified party (the “Indemnified Party”) shall give the indemnifying Party (the
“Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any Losses or discovery of facts upon which such Indemnified Party intends to base a request for indemnification under
Section 8.1 or 8.2, but in no event shall the Indemnifying Party be liable for any Losses that result from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount
of such Loss (to the extent that the nature and amount of such Loss are known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any Losses.

 (b) Third Party Claims. The obligations of an Indemnifying Party under this Article VIII with respect to Losses arising
from claims of any third Person that are subject to indemnification as provided for in Section 8.1 or 8.2 (a “Third Party Claim”) shall be governed by and be contingent upon the following additional terms and conditions:

 (i) Control of Defense. At its option, the Indemnifying Party may assume the defense of any Third Party Claim by
giving written notice to the Indemnified Party within thirty (30) days after the Indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of a Third Party Claim by the Indemnifying Party shall not be
construed as an acknowledgment that the Indemnifying Party is liable to indemnify any Indemnified Party in respect of the Third Party Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against any
Indemnified Party’s claim for indemnification. Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the Indemnifying Party,
which shall be reasonably acceptable to the Indemnified Party. In the event the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party shall immediately deliver to the Indemnifying Party all original notices and
documents (including court papers) received by any Indemnified Party in connection with the Third Party Claim. Subject to Section 8.3(b)(ii), if the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnifying Party shall not
be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim. In the event that it is ultimately determined that the
Indemnifying Party is not obligated to indemnify, defend or hold harmless a Salix Indemnified Party or Glenmark Indemnified Party, as applicable, from and against the Third Party Claim, the Indemnified Party shall reimburse the Indemnifying Party
for any and all costs and expenses (including attorneys’ fees and costs of suit) and any Losses incurred by the Indemnifying Party in its defense of the Third Party Claim with respect to such Salix Indemnified Party or Glenmark Indemnified
Party, as applicable. 

  
 40 

 (ii) Right to Participate in Defense. Without limiting Section 8.3(b)(i), any
Indemnified Party shall be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the Indemnified
Party’s own expense unless (A) the employment thereof has been specifically authorized by the Indemnifying Party in writing, (B) the Indemnifying Party has failed to assume the defense and employ counsel in accordance with
Section 8.3(b)(i) (in which case the Indemnified Party shall control the defense), or (C) the interests of the Indemnified Party and the Indemnifying Party with respect to such Third Party Claim are sufficiently adverse to prohibit the
representation by the same counsel of both parties under applicable law, ethical rules or equitable principles. 
 (iii)
Settlement. With respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim and that will not result in the Indemnified Party’s becoming subject to injunctive or other relief or otherwise
adversely affect the business of the Indemnified Party in any manner, and as to which the Indemnifying Party shall have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the Indemnifying Party shall have the sole
right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its sole discretion, shall deem appropriate. With respect to all other Losses in connection with
Third Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 8.3(b)(i), the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any
settlement or otherwise dispose of such Loss; provided that it obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). The Indemnifying Party shall not be liable
for any settlement or other disposition of a Loss by an Indemnified Party that is reached without the written consent of the Indemnifying Party. Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, no
Indemnified Party shall admit any liability with respect to, or settle, compromise or dispose of, any Third Party Claim without the prior written consent of the Indemnifying Party (which consent shall not be unreasonably withheld, conditioned or
delayed). 
 (iv) Cooperation. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the
Indemnified Party shall cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be
reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably
relevant to such Third Party Claim, and making employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party shall reimburse the
Indemnified Party for all its reasonable out-of-pocket expenses in connection therewith. 

  
 41 

 (v) Expenses. Except as provided above, the reasonable and verifiable costs and
expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any Third Party Claim shall be reimbursed on a calendar quarter basis in arrears by the Indemnifying Party, without prejudice to the
Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 

8.4 Insurance. 
 (a) Salix shall maintain (i) comprehensive general liability insurance written on an occurrence basis with a combined single limit for bodily injury and property damage of not less than [*] United
States Dollars ($[*]) and (ii) product liability/completed operations coverage with a per claim limit of not less than [*] United States Dollars ($[*]) (together, the “Salix Policies”). 

(b) Glenmark shall maintain (i) comprehensive general liability insurance in the amount of [*] United States Dollars ($[*]) and
(ii) public liability insurance in the amount of [*] United States Dollars ($[*]) (collectively, the “Glenmark Policies”). 
 (c) The Policies shall (i) be provided by an insurance carrier(s) acceptable to the other Party and (ii) show the other Party as additional named insured and loss payee, as its interests may
appear. Certificates of insurance for the Policies shall be furnished to the other Party within ten (10) days after the Amendment Effective Date. The Policies shall remain in effect throughout the Term of this Agreement and shall not be
canceled or subject to a reduction of coverage or any other modification without the prior written authorization of the other Party. 
 8.5 Limitation on Damages. 
 (a) EXCEPT WITH RESPECT TO THE GROSS NEGLIGENCE
OR INTENTIONAL MISCONDUCT OF A PARTY, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES, INCLUDING BUSINESS INTERRUPTION OR LOST PROFITS, WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT
LIABILITY OR OTHERWISE. 
 (b) EXCEPT FOR EACH PARTY’S RESPECTIVE INDEMNIFICATION OBLIGATIONS SET FORTH IN SECTIONS 8.1 AND
8.2 AND GLENMARK’S OBLIGATIONS IN RESPECT OF THE COMPOUND EQUIPMENT UNDER SECTION 2.13(d), EACH PARTY’S TOTAL LIABILITY UNDER THIS 

[*] Confidential treatment requested. 

  
 42 

 AGREEMENT SHALL IN NO EVENT EXCEED THE TOTAL FEES PAID BY SALIX TO GLENMARK DURING THE TERM
OF THIS AGREEMENT; PROVIDED, HOWEVER, THAT GLENMARK’S LIABILITY FOR RECALLS PURSUANT TO SECTION 2.17 SHALL IN NO EVENT EXCEED THE PURCHASE PRICE RECEIVED BY GLENMARK FOR THE BATCH(ES) GIVING RISE TO SUCH LIABILITY. 

ARTICLE IX. MISCELLANEOUS 
 9.1 Notices. All notices, requests and other communications hereunder must be in writing, specifically reference this Agreement in a prominent manner, and be delivered personally, by electronic
mail (i.e., E-mail) with delivery receipt requested or by recognized international courier, to the Parties at the following addresses or E-mail addresses: 

If to Salix to: 
 Salix Pharmaceuticals, Inc. 
 1700 Perimeter Park Drive 

Morrisville, North Carolina 27560 
 Attention: AVP, Pharmaceutical Development and Manufacturing 

E-mail: Joseph.Lockhart@Salix.com 

with copies (which will not constitute notice) to: 

Salix Pharmaceuticals, Inc. 
 1700 Perimeter Park Drive 
 Morrisville, North Carolina 27560

 Attention: General Counsel 

E-mail: Mark.Reeth@Salix.com 
 and 

  
 43 

 Covington & Burling LLP 

1201 Pennsylvania Avenue, N.W. 
 Washington, D. C. 20004 
 Attention: Edward C. Britton, Esq.

 E-mail: ebritton@cov.com 

If to Glenmark to: 
 Glenmark Pharmaceuticals Ltd. 
 B/2, Mahalaxmi Chambers 

22, Bhulabhai Desai Road 
 Mumbai-400 026 
 India 

Attention: Glenn Saldanha 
 E-mail: glenn_saldanha@glenmarkpharma.com 
 with a copy (which
will not constitute notice) to: 
 Glenmark Pharmaceuticals Ltd. 

B/2, Mahalaxmi Chambers 
 22, Bhulabhai Desai Road 
 Mumbai-400 026 

India 
 Attention: Rajesh Desai 
 E-mail: rajesh_desai@glenmarkpharma.com

 All such notices, requests and other communications will (a) if delivered personally to the address as provided in this Section, be
deemed given upon receipt, (b) if delivered by electronic mail to the E-mail address as provided in this Section 9.1, be deemed given on the next regular business day in the jurisdiction of receipt, and (c) if delivered by courier to
the address as provided in this Section 9.1, be deemed given upon receipt. Any Party from time to time may change its address, E-mail address or other information for the purpose of notices to that Party by giving notice specifying such change
to the other Party hereto. 
 9.2 Force Majeure. Neither Party shall be liable for delay in delivery or nonperformance in
whole or in part (other than a failure to pay any amount due hereunder), nor shall the other Party have the right to terminate this Agreement except as otherwise specifically provided in this Section 9.2, where delivery or performance has been
affected by a condition beyond such Party’s reasonable control, including fires, floods, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorism, insurrections, riots, civil commotion, strikes,
lockouts or other labor disturbances, acts of God or acts, omissions or delays in acting by any governmental authority; provided that the Party affected by such a condition shall, within ten (10) days of its occurrence, give notice to
the other Party stating the nature of the condition, its anticipated duration and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no 

  
 44 

 
greater scope and no longer duration than is reasonably required and the nonperforming Party shall use its commercially reasonable efforts to remedy its inability to perform. Notwithstanding the
foregoing, in the event the suspension of performance continues for [*] ([*]) days after the date of the occurrence, and such failure to perform would constitute a material breach of this Agreement in the absence of such force majeure event, the
non-affected Party may terminate this Agreement immediately by written notice to the affected Party. 
 9.3 Entire Agreement;
Amendment. 
 (a) Other than as set forth in 9.3(b), this Agreement, together with the Schedules and Exhibits
attached hereto, sets forth and constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises and representations, whether written or oral, with
respect thereto, including the Original Agreement, are superseded hereby. Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth herein. 

(b) Simultaneously with the execution and delivery of this Agreement, the Parties are entering into an Agreement for
Advance Against Commitment Fee providing for the placement by Salix with Glenmark of an advance payment in respect of the Commitment Fee (the “Advance Agreement”). In the event of a conflict between Sections 3, 4, 5, and 6 of the
Advance Agreement and the provisions of this Agreement, Sections 3, 4, 5, and 6 of the Advance Agreement shall prevail. With respect to a conflict between any other provisions of the Advance Agreement and this Agreement, this Agreement shall
prevail. 
 (c) No amendment, modification, release or discharge shall be binding upon the Parties unless in
writing and duly executed by authorized representatives of both Parties. 
 9.4 Further Assurances. Each Party shall duly
execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments as may be necessary
or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof or to better assure and confirm unto such other Party its rights and remedies under this Agreement.

 9.5 Successors and Assigns. The terms and provisions hereof shall inure to the benefit of, and be binding upon, Salix,
Glenmark and their respective successors and permitted assigns. 
 9.6 Dispute Resolution. Any dispute, controversy or
claim arising out of or relating to this Agreement or the breach, termination or validity thereof (each, a 
 [*] Confidential treatment
requested. 

  
 45 

 “Dispute”), shall be referred to a senior executive of each Party; provided that
each such senior executive is not involved in such Dispute. Such senior executives shall meet for attempted resolution of such Dispute by good faith negotiations within thirty (30) days after such Dispute is referred to such senior management
employees. In the event such senior management employees are not able to resolve such Dispute within such thirty (30) day period, then, at the election of either Party, such Dispute shall be decided by litigation. Any such litigation shall be
pursued in accordance with Section 9.7; provided that any dispute regarding the validity, scope, enforceability, inventorship or ownership of intellectual property rights shall be submitted by either Party to a court of competent
jurisdiction in the country in which such rights apply. 
 9.7 Governing Law; Jurisdiction; Venue; Service. 

(a) This Agreement shall be governed and interpreted in accordance with the law of the State of New York, excluding any
conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The Parties agree to exclude the application to this Agreement of the United
Nations Convention on Contracts for the International Sale of Goods. 
 (b) Subject to Section 9.6, each
Party irrevocably and unconditionally consents to the exclusive jurisdiction of the courts of general jurisdiction of the State of New York and the United States District Court for the Southern District of New York sitting in the Borough of
Manhattan (collectively, the “Courts”) for any action, suit or proceeding (other than appeals therefrom) concerning any matter arising out of or relating to this Agreement, and agrees not to commence any action, suit or proceeding
(other than appeals therefrom) related thereto except in such Courts. 
 (c) Each Party hereto further hereby
irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the Courts and hereby further irrevocably and
unconditionally agrees not to raise any objection at any time to the laying or maintaining of the venue of any such action, suit or proceeding in any of such Courts, irrevocably waives any claim that such action, suit or other proceeding has been
brought in an inconvenient forum and further irrevocably waives the right to object, with respect to such action, suit or other proceeding, that such Court does not have any jurisdiction over such Party. 

(d) Each Party hereto further agrees that, to the maximum extent permitted by Applicable Law, service of any process,
summons, notice or document by registered mail to its address and contact person for notices provided for in Section 9.1 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any of
the Courts. 

  
 46 

 9.8 Third Party Beneficiaries. Nothing in this Agreement shall be construed as giving
any person, firm, corporation or other entity, other than the Parties hereto and their successors and permitted assigns, any right, remedy or claim under or in respect of this Agreement or any provision hereof. 

9.9 Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical
information from the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under this
Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate
agency or other governmental entity in accordance with Applicable Law. 
 9.10 Assignment. Except as expressly provided
herein, neither Party may, without the prior written consent of the other Party, sell, transfer, assign, delegate, pledge, subcontract or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or
any of its rights or duties hereunder; provided, however, (a) Salix may, without the prior written consent of Glenmark, assign this Agreement and its rights and obligations hereunder to the purchaser or sublicensee of Salix’s
rights in and to the Compound or any Product and (b) either Party may, without the prior written consent of the other Party, assign this Agreement and its rights and obligations hereunder to any of its Affiliates or the purchaser of all or
substantially all of its assets or to any successor entity or acquirer in the event of a merger, consolidation or change in control of such Party. Any attempt to assign, transfer, subcontract or delegate any portion of this Agreement in violation of
this Section shall be null and void. All validly assigned and delegated rights and obligations of the Parties hereunder shall be binding upon and inure to the benefit of and be enforceable by and against the successors and permitted assigns of Salix
or Glenmark, as the case may be. In the event either Party assigns or delegates its rights or obligations to another Person in accordance with the terms hereof, the assignee or transferee shall assume all obligations of its assignor or transferor
under this Agreement and the assignor or transferor shall cease to be a party to this Agreement and shall cease to have any rights or obligations under this Agreement from and after the effective date of such assignment. Notwithstanding the
foregoing, no such assignment or delegation shall relieve the assignor or transferor of any of its obligations hereunder. Notwithstanding anything to the contrary herein, Glenmark may not subcontract or delegate any of its obligations under this
Agreement to any Person without the prior written consent of Salix, which consent shall not be unreasonably withheld, conditioned or delayed. 
 9.11 Waiver. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a
written instrument duly executed by or on behalf of the Party waiving such term or condition. No waiver by either Party of any term or condition of this Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of the
same or any other term or condition of this Agreement on any future occasion. 

  
 47 

 9.12 Severability. If any provision of this Agreement is held to be illegal, invalid
or unenforceable under any present or future law, and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision shall be fully severable, (b) this Agreement
shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the
illegal, invalid or unenforceable provision or by its severance herefrom, and (d) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable
provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties herein. 
 9.13 Independent Contractors. The status of the Parties under this Agreement shall be that of independent contractors. Nothing in this Agreement is intended or shall be deemed to constitute a
partnership, agency, employer, employee, or joint venture relationship between the Parties. Neither Party shall have the right to enter into any agreements on behalf of the other Party, nor shall it represent to any Person that it has any such right
or authority. 
 9.14 Construction. Unless the context of this Agreement otherwise requires: (a) words of any gender
include each other gender; (b) words using the singular or plural number also include the plural or singular number, respectively; (c) the terms “hereof,” “herein,” “hereby” and derivative or similar words
refer to this entire Agreement; (d) the terms “Article,” “Section,” “Schedule,” “Exhibit” or “clause” refer to the specified Article, Section, Schedule, Exhibit or clause of this Agreement;
(e) the term “or” has, except where otherwise indicated, the inclusive meaning represented by the phrase “and/or”; (f) the term “including” or “includes” means “including without
limitation” or “includes without limitation”; and (g) references to any agreement, instrument or other document in this Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently
amended, replaced or supplemented from time to time, as so amended, replaced or supplemented and in effect at the relevant time of reference thereto. Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless
business days are specified. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend, or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The
language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party. 
 9.15 Remedies. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by applicable law or otherwise available except as expressly set forth
herein. 
 9.16 Counterparts; Facsimile Execution. This Agreement may be executed in any number of counterparts, each of
which shall be deemed to be an original, and all of which, taken together, shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement (and each amendment, modification and waiver in
respect of it) by facsimile or other electronic transmission shall be as effective as delivery of a manually executed original counterpart of each such instrument. 

  
 48 

 9.17 English Language. This Agreement shall be written and executed in, and
all other communications under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof, and in the event of any conflict in interpretation between the
English version and such translation, the English version shall control. 
 9.18 Attorneys’ Fees. If a Party is
determined to be in breach of this Agreement by a court of competent jurisdiction, such Party shall be responsible to the prevailing Party for any and all reasonable out-of-pocket expenses, including attorneys’ fees and court costs actually
incurred by the prevailing Party by reason of its enforcement and protection of its rights under this Agreement, as determined by such court. 
 [The remainder of this page has been intentionally left blank.] 

  
 49 

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement on the day and year
first above written. 
  

							
	SALIX PHARMACEUTICALS, INC.	 		 	GLENMARK PHARMACEUTICALS LTD.
				
	 By: /s/ Carolyn J. Logan
	 		 	By:	 	/s/ Glenn Saldanba
				
	 Name: Carolyn J. Logan
	 		 	Name:	 	Glenn Saldanba
				
	 Title: President and CEO
	 		 	Title:	 	Chairman & Managing Director

 Schedule 1.5 
 Agreed Scale-Up Plan 
 [*] 
 [*] Confidential treatment requested. 

 Schedule 1.24 
 Current Capacity 
 [*]. 
 [*] Confidential treatment requested. 

 Schedule 1.37 
 Fully-Allocated Manufacturing Costs 
 As used in this
Agreement, “Fully-Allocated Manufacturing Costs” or “FAMC” means: 
  

	I.	[*]. FAMC shall not include [*] and other [*] or [*] or [*] or [*]. 

 For such purposes: 
 A. Direct material costs include: 

1. The cost of [*] [*][*] (i.e., [*], [*], etc. to the extent [*] and [*] and more appropriately captured by Item I.C.2.
(below), [*] and other [*] used in the production of a Compound. 
 2. [*] and [*] (exclusive of [*] in excess of
[*] for Compound.) 
 B. Direct labor costs include: 

1. [*] and [*] for [*]. 
 C. Manufacturing overhead is limited to costs that can be identified in a practical manner with specific units of production in accordance with IFRS but cannot be included in specific direct material or
direct labor costs. Such overhead costs may include: 
 1. [*], including, but not limited to, [*] (e.g., [*]),
[*] and [*], [*] (e.g., [*]), [*] and [*] (excluding [*]) and [*] with respect to the Compound at the Facility. 

2. [*], including [*] including [*], [*] (including [*]), [*] to be [*] in connection with the Manufacture of the Compound
at the Facility. 
 3. [*] and [*] [*] [*] of [*] [*] [*] . 

D. Allowances for manufacturing variances, including yield variances within GMP tolerances. 

E. Allowances for adjustments to inventory, valuation, including reasonable charges for spoilage, expiration of shelf life and like
charges related to the Compound Manufactured at the Facility. 
 [*] Confidential treatment requested. 

 F. Property and sales taxes on shipment and warehousing related to finished
goods. 
  

	II.	FAMC does not include: 

 A. [*] 
 B. [*] 

C. [*] 
 D. [*] 
 E. [*] 

F. [*] 
 G. Costs associated with the [*] and the [*], including, without limitation, the costs of [*] and other [*]. 
 H. [*] 
 I. [*] 

J. [*] 
  

	III.	Adjustments for Glenmark Inventions0 

 In the event that (a) any Glenmark Inventions come into existence during the Term, (b) such Glenmark Inventions result in a reduction of the then-current FAMC, and (c) Salix has the
Compound Manufactured using such Glenmark Inventions, then the FAMC shall be increased by an amount equal to [*] percent ([*]%) of the amount of any such reduction in FAMC (the “Markup Amount”) if such Manufacture is performed by
Glenmark. If such Manufacture is performed by a Third Party Manufacturer pursuant to a Third Party Manufacturer License, then the markup set forth in Section (B) of Schedule 2.5(b) shall be increased by [*]. 

[*] Confidential treatment requested. 

 Schedule 1.46 
 Glenmark Territory 
 [*] 
 [*] Confidential treatment requested. 

 Schedule 1.89 
 Specifications 
 Compound-Related Specifications 

[*] 
 [*] Confidential treatment requested.

 CPL-Related Specifications 
 [*] 
 [*] Confidential treatment requested. 

 Schedule 1.97 
 Third Party Manufacturer License 
 A Third Party Manufacturer License shall be a
non-exclusive license to use the Glenmark Inventions and the Glenmark Information solely for the purpose to Manufacture the Compound for supply to Salix. 

 Schedule 2.2(c) 

Full Production Lot Sizes 

[*] 
 [*] Confidential treatment requested.

 Schedule 2.5(b) 

Compensation to Glenmark for Use of 
 Third Party Manufacturer 
 In the event that Salix uses a Third Party
Manufacturer at any time during the Term of this Agreement from the Effective Date until the [*] anniversary thereof, Salix shall compensate Glenmark for any such use as follows: 
 (A)        So long as Glenmark is ready, willing and able to supply Salix’s [*] for Compound, Salix may purchase Compound from a Third Party Manufacturer
without any markup so long as Salix purchases no more than [*] ([*]%) of its total requirements for Compound from the Third Party Manufacturer; 

(B)        If Glenmark is ready, willing and able to supply Salix’s [*] for Compound and Salix purchases
Compound from a Third Party Manufacturer more than [*] ([*]) of its [*] for Compound, then Salix shall pay Glenmark a markup of [*] ([*]) of the [*] to the Third Party Manufacturer for the quantities in excess of [*] [*] ([*]); 

(C)        If Glenmark is unable to supply Salix’s [*] for Compound, Salix may purchase from a Third Party
Manufacturer [*] of Compound as [*] to Salix, so long as Glenmark’s inability to supply is not the direct result of Salix’s breach of its obligations under this Agreement or Salix’s willful misconduct. In such event, Glenmark may
resume supply of Compound to Salix for at least [*] [*] ([*]) of Salix’s [*] of Compound upon [*] ([*]) [*] prior written notice of its intention to resume supply of Compound for at least [*] percent ([*]) of Salix’s [*] of Compound. Salix
shall resume its relationship with Glenmark in such capacity [*]; provided that Salix has fulfilled its purchase requirement to its Third Party Manufacturer, which in no event shall be more than [*] ([*]) [*] from receipt of such notice by
Salix from Glenmark. 
 (D)        If Glenmark’s inability to supply is the result of Salix’s
breach of its obligations under this Agreement or Salix’s willful misconduct, then Salix shall [*]. 
 [*] Confidential treatment
requested.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}]]